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Abstract
The tricarboxylic acid (TCA) cycle is a central route for the energy production via
oxidative phosphorylation and is ubiquitous throughout nature. Apart from playing a major role
in energy provision, it is also essential for a wide range of physiological functions in any
organism. Although an increasing emphasis is laid on the interlinking role of the cycle, its
regulation and control are less very less understood. As the field progresses, the consequences of
TCA cycle anomalies are shown to be tied to various cancers and other disorders. The matter
becomes more complex when considering the varying functions of the isozymes present in the
cycle.
The repertoire of twenty amino acids that is present in almost all organisms makes up for
the hundreds of proteins responsible for the basic functioning of an organism. In order to
synthesize a wide spectrum of viable proteins, one of the methods that the cells utilize is posttranslational modifications. These modifications can be reversible depending on the conditions
and they render conformational changes to the protein, thereby influencing its enzyme activity or
labeling them for transportation or degradation. One such post-translational modification is
acetylation, which is the main focus of this project. Acetylation is predominantly seen across all
domains of life, and in spite of the prevalence of this modification, it is only recently that with
the advances in technology the basic role of acetylation is being understood. However, there are
still many questions that need to be answered to recognize the complete role of protein
acetylation.
Recently, a newer technique has been adopted to study the impact of post-translational
modifications. The genetic code expansion strategy helps in the incorporation of a noncanonical
amino acid into a distinct position, thereby giving rise to a customized protein. It uses stop codon

suppression to insert the unnatural amino acid. The pyrrolysyl-tRNA synthetase and its cognate
tRNA were used in this project to create TCA cycle enzymes with acetyllysine.
In this dissertation, I examine the changes caused in the enzymes, malate dehydrogenase,
isocitrate dehydrogenase, and citrate synthase, of the TCA cycle in response to acetylation of
specific lysine residues and deduce the potential mechanisms regulating these changes. In doing
so in E. coli, a greater understanding of protein acetylation is achieved and its implications on
modulating functions are examined.
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CHAPTER I
INTRODUCTION
1.1 Tricarboxylic Acid Cycle
The tricarboxylic acid (TCA) cycle also called the citric acid cycle or the Kreb’s cycle is
a central pathway consisting of a series of steps for the oxidation of acetyl CoA to release
adenosine triphosphate (ATP) and carbon dioxide (CO2) (Figure 1.1).

Figure 1.1 Schematic representation of TCA cycle. It shows the reactions facilitated by eight
enzymes in the mitochondrial matrix of eukaryotes [1]. The cycle results in the production of
NADH and FADH2 which in turn donate electrons via electron transport chain (ETC) to generate
ATP from oxidative phosphorylation.
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The Kreb’s cycle was first proposed in 1937 by Hans Adolf Krebs, a German-British
scientist who later was awarded the Noble Prize in physiology in 1953. It is an energyproducing pathway of the respiratory metabolism that produces NADH and FADH2, which will
be channeled to the electron transport chain in the mitochondria of eukaryotes [2].
In prokaryotes, this sequential process is performed in the cytosol with the proton
gradient for ATP being made across the cell membrane. A similar pathway in the eukaryotes
occurs, with the difference that the reaction takes place in the mitochondrial matrix. Two rounds
of the citric acid cycle have an overall yield of 6 NADH, 2 FADH2, and 2 ATP which accounts
for 24 ATP in total [3].
Apart from its role in respiration, amino acid biosynthesis, and nitrogen metabolism in
plants, TCA cycle also impacts cellular redox balance and biotic stress responses [4]. It is an
exergonic in nature and predominant in aerobic organisms. The evolutionary origin of the TCA
cycle is long considered to be a reductive version of it rather than the commonly observed
oxidative one. The reductive form is a non-Calvin type of carbon dioxide fixating pathway seen
in organisms like Aquificales and was first reported in Chlorobium limicola, a green sulfur
photosynthetic bacteria [5].
Although the TCA cycle is most times considered to be a unidirectional route, there are
other pathways that the metabolites can follow from or into. This is simply proven by the fact
that the only reactions that are irreversible in the cycle are mediated by citrate synthase and ketoglutarate dehydrogenase [6]. An extraordinary role of connecting gluconeogenesis,
transamination, deamination, and lipogenesis is accomplished by the TCA cycle [7] however,
unlike other metabolic pathways, very few genetic disorders and diseases associated with the
TCA cycle are known. Nevertheless, it is also to be noted that in the recent years, many research
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groups are actively involved in emphasizing the versatility of this pathway and the intricacies it
poses in maintaining the homeostasis of the body.

1.1.1 Evolution of the TCA cycle
It has always been intriguing to unravel the factors that stimulated the origin of life on
earth. The proof of cellular life dates back to somewhere between 3.5 to 4 billion years ago [8],
but the earth was shown to be reducing or neutral only 2 billion years ago [9]. The basis to
comprehend the beginning of life forms lies in investigating the emergence of the metabolic
pathways. It is considered that protein cofactors would have mediated the proto-metabolic
reactions even before the protein-mediated pathways came into existence. In some cases,
Fe/Ni/S-electron transfer cofactors that function in relation to the acetyl CoA pathway enzymes
still bear some comparisons to the reactive geological period [10].

Figure 1.2 Representation of the reductive TCA cycle. It is considered the precursor of the
oxidative cycle and helps in carbon dioxide fixation and serves to stir the production of major
biomolecules [11].
TCA cycle is the most studied pathway to understand early life [12]. Enzymes of the
TCA cycle are considered ancient from its homology that is seen across bacteria, archaea, and
3

eukaryotes. Ever since, researchers have proposed many variants of the TCA cycle which
include 1) reductive TCA cycle, 2) alternative oxidative cycle, and 3) variant with
acetate:succinate CoA-transferase (ASCT) instead of succinyl-CoA synthetase [13]. The
oxidative direction of the TCA cycle transforms organic compounds into reducing counterparts.
These assist biosynthetic reactions that maybe otherwise unfavorable or participate in ATP
production through oxidative phosphorylation. The reductive TCA (rTCA) cycle, also called the
reverse Krebs cycle, or Arnon cycle helps in the fixation of carbon dioxide [14]. rTCA is the
precursor of an aerobic TCA cycle leading to the synthesis of amino acids, carbohydrates, lipids,
nucleobases, and other metabolic intermediates [10] (Figure. 1.2).
Mycobacterium has always raised ambiguities in understanding its pathogenesis and
other metabolic functioning. Traditionally, the TCA cycle in aerobic and anaerobic organisms
distinctly varies. Contrarily, Mycobacterium tuberculosis (M. tb) is known to survive under
drastic hypoxic conditions (0.28 mm Hg i.e., 0.03%), while being an aerobic bacterium [15].
This drew attention to the possibilities of variation of the TCA cycle in M. tb. Previously, it was
indicated that α-ketoglutarate dehydrogenase was absent in M. tb and so, the succinic
semialdehyde (SSA) variant of TCA cycle was assumed to be functional. On the contrary,
recently, researchers have identified CoA-dependent α-ketoglutarate dehydrogenase in M. tb,
which is typically found in anaerobic bacteria. This ketoglutarate: ferredoxin oxidoreductase
(KOR) is tested to be highly stable even under aerobic conditions, which is exceptional to other
enzymes in this family. KOR has been shown to complete the oxidative TCA in M. tb with two
pathways: 1) KOR dependent in the presence of β-oxidation and 2) succinic semialdehyde
dependent in the absence of β-oxidation [16].
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The variants seen in the TCA cycle imposes its significance across all life forms and it
becomes inevitable to study in detail the regulation of this cycle and its role in maintaining the
delicate balance of metabolites.

1.1.2 Role of TCA cycle in the synthesis of biomolecules
Metabolites produced as a result of TCA cycle form precursors for a number of
biomolecules including amino acids, nucleic acids, fatty acids, and porphyrins. This shows the
amphibolic nature of the cycle as it performs both catabolism and anabolism.

Amino Acids biosynthesis
All amino acids are synthesized as a resultant from the intermediates of glycolysis, citric
acid cycle, or pentose phosphate pathway. While organisms like E. coli can synthesize all 20
amino acids, humans depend on dietary supplementation of 9 essential amino while the others
are called non-essential amino acids.
α-ketoacids, α-ketoglutarate, and oxaloacetate of the TCA cycle play a vital role in the
production of amino acids. The hexameric enzyme glutamate dehydrogenase (GDH) catalyzes
the reversible conversion of α-ketoglutarate and ammonia to glutamate [17].
NH4+ + α-ketoglutarate + NADPH +H+ ⇌ glutamate + NADP+ +H2O
Consequently, the amino group from glutamate is transferred to other metabolites such as
oxaloacetate in the case of TCA cycle, by transamination reaction to produce aspartate. These
reactions are catalyzed by pyridoxal phosphate-dependent transaminases [18].
Oxaloacetate + glutamate ⇌ aspartate + α-ketoglutarate

5

Conversion of aspartate and glutamate to asparagine and glutamine, respectively are
chemically analogous [19]. Biosynthesis of proline, which is a cyclized derivative of glutamate,
is obtained by the reaction between ATP and γ-carboxyl group of glutamate yielding an acyl
phosphate. This, in turn, is reduced to glutamate γ-semialdehyde, which is cyclized and reduced
to form proline. The glutamate γ-semialdehyde in this pathway can also form arginine without
cyclization. Other amino acids namely, methionine, threonine, and lysine are synthesized from
aspartate [20].

Porphyrins biosynthesis
Porphyrins which are necessary for the formation of heme and chlorophyll are
synthesized by the condensation reaction of glycine and succinyl-CoA. The product of this
reaction, δ-aminolevulinate, is formed by the catalysis of δ-aminolevulinate synthase and shapes
the basis for the complex structure of porphyrins[21]. Recently, it has been studied that during
late phases of erythropoiesis, δ-aminolevulinate could undergo deamination with glutamine as its
precursor, and lead to the conversion of α-ketoglutarate to succinyl-CoA catalyzed by αketoglutarate dehydrogenase (KDH). This process is suggested to take place without passage
through the TCA cycle but with the direct involvement of δ-aminolevulinate synthase and KDH
[22].

1.1.3 Role of TCA cycle in other processes
Interplay of the TCA cycle is observed in many processes other than just metabolism.
This is distinct from the anaplerotic nature of the pathway and its discrete function in different
cells for different conditions. The critical features of mitochondrial regulations are survival,
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activation, and differentiation of immune cells [23]. The functioning of M2 macrophages
involved in anti-inflammatory responses is dependent on the completion of the TCA cycle, while
M1 macrophages break the pathway into two stages to accumulate itaconate, a microbicide
compound, and succinate which aids in hypoxia inducible factor 1α (HIF1α) stabilization [24,
25]. Furthermore, many TCA cycle metabolites are suggested to function as inflammatory
response biomarkers for autoimmune diseases, sepsis, and systemic infection [26]. It has also
been indicated that in the diabetic state, energy metabolism including glucose absorption and
TCA cycle is disrupted for which many medicinal plants are studied by researchers to maintain
homeostasis of pyruvate, which in turn would increase the metabolites of TCA cycle [27].
Apart from the direct involvement of TCA in the immune response, the metabolites
produced in the process render dendritic cells (DC) activation and other inflammatory functions.
Acetyl CoA and oxaloacetate assist in the synthesis of fatty acids and sterols. This in turn plays a
critical role in the membrane construction and expansion, required for DC antigen presentation.
Expansion of endoplasmic reticulum and Golgi leads to the production of proteins necessary for
the activation and functioning of macrophages [28].
Modulation of TCA cycle metabolites in influenza A virus infected cells were studied to
discover the value of immunometabolism. On infecting H1N1 virus into A549 adenocarcinomic
human alveolar basal epithelial cells, it was found that enzymes of the TCA cycle remained
intact during the first replication cycle (0-8 hours). It is implied that the stability of TCA cycle
was crucial for viral replication and so the mitochondrial energy was maintained by upregulating the glutamate produced [29].
Isozymes of TCA cycle enzymes are present in mitochondria (isocitrate dehydrogenase
[ICDH] 2) and cytosol (ICDH1 and malic enzyme/ME1) [30]. They are involved in the synthesis
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of NADPH, which acts as a cofactor to reduce oxidized glutathione (GSSG→2GSH) and
thioredoxin for glutathione reductase (GR) and thioredoxin reductase, respectively. Glutathione
peroxidases (GPX) in the liver oxidizes glutathione and is an antagonist to GR. It has been
studied that these biomolecules, glutathione and thioredoxin, play a role against oxidative stress
[31] and promote endoplasmic reticulum (ER) protein synthesis.

A.

B.

Figure 1.3 The illustration of the role of TCA cycle in ER stress. It shows the depiction where
A. the mitochondrial pyruvate carrier (MPC) activation increased the NADPH production,
thereby elevating ER stress. B. shows the deletion of MPC and the reduction in TCA cycle
resulted in alleviation of ER stress and protected the liver from steatohepatitis in relation to
glutathione peroxidase 1 (GPX1).
When a disease such as obesity and its associated disorders disrupt the protein biogenesis
process, it causes stress on ER. With further investigation into the direct role of TCA cycle on
ER stress, it was found that inhibiting either TCA-dependent NADPH production or glutathione
reductase aided in reducing ER stress (Figure 1.3). This data was corroborated when
mitochondrial pyruvate carrier (MPC) was knocked out in hepatocytes to inhibit TCA cycle. It is
understood that ER estimates mitochondrial metabolic activity with NADPH and GSSG levels.
When acetyl CoA availability decreases, it leads to a reduction in NADPH and thus dampens

8

glutathione reduction. Consequently, ER oxidative state is altered, and ER homeostasis is
maintained. This pattern is also visible in other cell types such as myocytes and brown
adipocytes [32].

1.1.4 TCA cycle in cancer
There have been developing evidence which point to the idea that cancer is mitochondrial
in nature and mutations in TCA enzymes such as isocitrate dehydrogenase (ICDH), succinate
dehydrogenase (SDH), fumarate hydratase (FH), and malate dehydrogenase (MDH) have been
observed in some tumors [33, 34] (Table 1.1). This is caused by the imbalance in metabolites and
cytoplasmic levels of acetyl CoA, thereby manipulating crucial proteins that cause tumorigenesis
by acetylation [35]. Furthermore, acute myeloid leukemia is characterized by the involvement of
TCA cycle with glutamine as its fuel [36]. On the contrary, there have also been studies
suggesting that glutamine acts as a fuel for the TCA cycle may not confer tumor growth but the
advantage may be interconnected to its relation with other pathways [37]. Additionally,
hepatocellular carcinoma is also influenced by aconitase (ACO2) and ICDH with their interplay
in the upregulation of NF-κB, HIF, and mitochondrial signals [38].
Lan Huang et al., have reviewed the role of citrate in the development, survival, and
expansion of cancer. Citrate is known to play dual roles in tumor prognosis. There have been
studies that support the anti-tumor effects of citrate showing a reduction in tumor size and
proliferation rate. On the contrary, there have also been researches to show the tumor growth
promotion and metastatic characteristics promoted by citrate. Recently, efforts to develop citrate
as a biomarker for cancer diagnosis are being made, especially in the case of prostate cancer.
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Understanding the vital role of citrate in cancer has in turn, led to the attention of citrate synthase
(CS) and aconitase 2 (ACO2), which control the concentration and fate of citrate [28].
Role of TCA cycle in the production of monoclonal antibody (mAb) has been elucidated
by examining Chinese hamster ovary (CHO) cells. CHO cells are predominantly used in the
production of mAb but the bottleneck in this method is the Warburg effect that leads to excessive
lactate production. To improve the efficiency of this process, stimulation of TCA cycle activity
and mitochondrial respiration was tested. When α-lipoic acid, a pyruvate dehydrogenase
activator, was used to aid the anaplerosis of this cycle, it showed process improvement but
resulted in saturation of mitochondria. To balance this effect, the mitochondrial capacity was
improved using methylene blue. The combinational use of these drugs yielded an 24% rise in
mAb production with lowered stress signals [39]. Thus, the modulation of TCA cycle not only
plays a role in metabolic regulation but indirectly controls a number of industrial applications.
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Table 1.1 Depiction of different types of cancer which are caused by the dysfunction of
some TCA cycle enzymes[33] [28].
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1.1.5 Enzymes of the TCA cycle concentrated on in this project
1.1.5.1 Malate Dehydrogenase
Malate dehydrogenase, an enzyme of the TCA cycle, reversibly oxidizes L-malate
(MAL) to oxaloacetate (OAA) accompanied by the conversion of NAD+ to NADH [40]. This
enzyme is present in many isoforms most of which are NAD+-dependent except for the MDH
isoform present in the chloroplast which is NADPH dependent. In eukaryotes, MDH1 and
MDH2 are present in the cytoplasm and mitochondria, respectively. MDH2 is the enzyme that
participates in the TCA cycle, while MDH1 is the enzyme in the malate/aspartate shuttle. Both
isozymes are present as dimers with molecular mass of the monomer being ∼35 kDa and is
allosterically regulated by citrate, while inhibited by 2-thenoyltrifluoroacetone, adenosine mono-,
di-, tri-phosphate, fumarate, citrate, and aspartate, and high OAA concentrations [41]. Another
isoform which converts malate from glyoxylate cycle in yeast is present in the glyoxysomes.
MDH2 in eukaryotes is analogous to the MDH present in some eubacteria such as E. coli and
MDH present in chloroplast and cytoplasm show sequence similarities with other eubacteria
including Thermus flavus. This fact favors the endosymbiotic theory for the evolution of
mitochondria and chloroplasts [42].
Structurally, MDHs are stable dimers consisting of structural and functional domains of
each subunit. The N-terminal consists of the NAD+-binding domain with a parallel β-sheet
structure, while the C-terminal comprises of the substrate binding domain and two domains are
attached to each other with a cleft that forms the active site of the enzyme [42].
MDH has been implicated with a number of processes that cause various diseases. In
cancer, there have been evidence to support that both MDHs present in the mitochondria and
cytoplasm could be potential targets against cancers to maintain the required redox states [43]. It
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has also shown that MDH1 regulates early stages of autophagy responsible in pancreatic ductal
adenocarcinoma survival [44]. In a degenerative disorder like Creutzfeldt-Jakob disease,
mitochondrial MDH has been expressed at elevated levels than in comparison to the control
paving ways to be used for diagnostic purposes [45]. Similarly, anomalies in both MDH1 and
MDH2 have been associated with the early onset of severe encephalopathy [46] [47]. In addition,
MDH also plays a role in metabolic diseases such as diabetes and helps in gaining further
knowledge on the pathogenesis of Mycobacterium [48, 49] and Brucella [50]. These studies,
therefore, prove MDH to be a potential candidate to develop therapeutics by understanding its
role in maintaining homeostasis.

1.1.5.2 Isocitrate Dehydrogenase
Isocitrate dehydrogenase is a crucial enzyme associated with many types of cancers. It
has three isoforms: ICDH1 located in the cytoplasm and peroxisomes and ICDH2 and ICDH3 in
the mitochondria.
ICDH1 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate
accompanied with the conversion of NADP+ to NADPH reversibly, while the same reaction is
carried out in the mitochondria by ICDH2. Structurally, both enzymes are homodimers and play
an important role in oxidative stress. Alternatively, the reverse reaction influences lipogenesis
and glycolysis regulation. In contrast to ICDH1 and ICDH2, ICDH3 catalyzes the irreversible
oxidative decarboxylation of isocitrate to α-ketoglutarate with the reduction of NAD+ to NADH.
This isoform is a heterotetramer consisting of two α-subunits, one β, and one γ-subunit and is
subjected to allosteric regulation. It is activated by calcium, ADP, and citrate, while inhibited by
ATP, NADH, and NADPH [51].
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Increasing interest in the impact of ICDH on cancer is fast growing because of its
diagnostic and prognostic value [52]. In the last decade, nearly 3000 research papers have been
published that interrelate the functions of ICDH to cancer. Aberrant ICDH expression has been
observed in acute myeloid leukemia, angioimmunoblastic lymphomas, chondrosarcoma, gliomas
[53], intrahepatic cholangiocarcinoma, and thyroid carcinomas [54]. In most cancer, mutations of
ICDH1/2 have only been observed, while ICDH3 has no noticeable impact on cancer. When a
mutation takes place in ICDH, it results in the formation of a neomorphic enzyme that
accelerates the conversion of α-ketoglutarate to D-2-hydroxyglutarate (D2HG) and accumulation
of D2HG is used as a biomarker to identify such aberrations. Many drugs have been developed
to inhibit the activity of ICDH1/2 and are being tested at different stages of clinical and preclinical studies. It has also been suggested that ICDH alter the expression of immunogenic
cytokines and receptors, thereby making it a target for immunotherapy. Thus, immediate stress is
laid on comprehending the ways to modulate ICDH activity and mutations to deliver therapeutic
approaches that benefit against cancer.

1.1.5.3 Citrate Synthase
Citrate synthase (CS) is the first enzyme in TCA cycle and is a rate-limiting enzyme. As
the TCA cycle occurs in the matrix of the mitochondria, CS is transported from the cytoplasm to
the mitochondria and is known to play a pivotal role in producing energy and apoptosis in
different cell types. Two isoforms of CS are identified in the mitochondria and peroxisomes of
Saccharomyces cerevisiae and Arabidopsis thaliana [55]. Modulation of expression levels of CS
has a direct effect of ATP production, excessive superoxide formation and cell apoptosis [56].
The importance of CS in the pathogenesis of various organisms has been studied including
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Klebsiella pneumonia [57] and Echinococcus granulosus [58]. CS plays a specific role in renal
health and it is suggested that there could be a viable defense against progressive renal injury
under decreased CS activity [59]. It has been studied that CS is connected to the Warburg effect
causing malignancy [60] and is also linked to different cancers including pancreatic, ovarian,
cervical, and breast cancer. It can either be characterized by increased or decreased activity
depending on the tissue type [28]. With increasing evidence suggesting the role of CS in
tumorigenesis and other processes, it becomes important to investigate the consequences of
manipulating its expression and enzyme activity under varying conditions.

1.2 Post-translational Modification
Commonly the 20 natural canonical amino acids are encoded by 61 triplet codons in
addition to the three stop codons. While these amino acids make up for the complete protein
composition in most organisms, for them to become functionally capable to carry out different
processes they undergo further modifications, either co-translationally or post-translationally.
Post-translational modifications (PTMs) play a pivotal role in regulating protein activity,
compartmentation, transcription, and cellular signaling and the major PTMs include
phosphorylation, acetylation, methylation, and ubiquitination [61] (Figure 1.4).

1.2.1 Implications of PTMs in the human body
The diversity of peptide modifications is long-established, but a renaissance of interest
has been noticed in understanding their role in molecular mechanisms that control homeostasis
of the body. These new insights answer questions that help connect different pathways and
networks that control fundamental biological processes. Anomalies in PTMs lead to various
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diseases such as neurodegenerative disease [62-64], heart disease [65], cancer [66, 67] and agerelated disorders [68, 69].

Figure 1.4 Schematic representation of different post-translational modifications. It depicts
the modifications that can be separated into five general classes: reversible addition of chemical
groups or complex molecules or polypeptides to specific amino acids and irreversible amino acid
modification or cleavage of the peptide bond between residues, known as proteolysis [70].

1.2.2 Acetylation
Acetylation is the transfer of acetyl group from acetyl CoA to the α-amino group of
the N-terminus of proteins (irreversible) or to the ε-amino group of lysine amino acids
(reversible) by N-acetyltransferase (NAT) and is reversibly removed by deacetylases. It is one of
the major PTMs and has been found that nearly 80-90% of eukaryotic proteins are acetylated. In
spite of the underpinning role of acetylation in different biological process including
transcription, replication, recombination, repair, translation, apoptosis, stress control, and
membrane trafficking [71], it is not until recently that the significance of acetylation is gaining
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attention. Acetylation of histone proteins on chromatin regulates gene transcription and, in this
case, histone acetyltransferases (HATs) and histone deacetylases (HDACs) catalyze the transfer
of the acetyl group to and from an amino acid. Therefore, acetylation and methylation of histones
affect the overall transcriptome of an organism. For other non-histone proteins, lysine
acetyltransferases (KATs) and lysine deacetylases (KDACs) perform the addition and removal of
acetyl group, respectively (Figure 1.5). Three families of KATs have been identified with
members: GNAT family, MYST family, and p300/CBP (CREB-binding protein) family.

Figure 1.5 Exemplification of the acetylation process. Acetyl CoA acts as an acetyl donor
whereas KAT and KDAC execute the reversible transfer of acetyl group of the protein [72]. This
reversible acetyl transfer is involved in the regulation of protein functions.
Sirtuins are a family of NAD+ (nicotine adenine dinucleotide)-dependent deacetylases
and functions in gene silencing by hypoacetylation and maintain genomic stability. The second
family of KDACs is Zn2 +-dependent HDACs which consists of three classes: Class I, II, and IV
[71]. They are concentrated in the nucleus and the cytoplasm, while sirtuins are also present in
the mitochondria. It is also known to crosstalk with other PTMs such as phosphorylation,
ubiquitination, and methylation [73].
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To regulate Tau assembly and function, phosphorylation and acetylation appear to
crosstalk. Tau liquid-liquid phase separation and aggregation is decreased on lysine acetylation.
Also, phosphorylation of Tau is inhibited upon acetylation of Lys-321, thereby preventing its
function and promoting aggregation. Similar mechanisms are detected in ribosome binding
proteins such as TDP-43 [74] which make up the ribonucleoproteins. Recently, the role of
acetylation, phosphorylation, and methylation in lung cancer were studied in an effort to develop
new therapeutics for lung cancer patients and illustrate how the PTMs control different cell
signaling pathways [75].

1.2.2.1 Role of Lysine Acetylation in Physiology
As lysine acetylation impacts many cellular processes, it is inevitable that it plays a role
in influencing the physiology of an organism. When acetylation takes place with acetyl CoA as a
donor, it releases negatively charged acetate anions decreasing the pH. In this condition, the
histones become hypoacetylated and push the anions and protons outside the cell. Conversely, in
actively proliferating cells, as the pH increases, histones are hyperacetylated. Furthermore, it has
been observed that acetylation patterns vary in different cell types in diverse conditions.
Neuronal activities undergo crosstalk of acetylation and phosphorylation through MAPK-ERKpathway and when this balance is disturbed, it leads to cognitive deterioration. Moreover, similar
processes affect the pluripotency and cause developmental issues [76].

1.2.2.2 Role of Lysine Acetylation in Diseases
Failure to maintain a tight balance between acetylation and deacetylation is associated
with a number of clinical conditions such as neurodegenerative diseases, cancer, cardiac
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hypertrophy, diabetes, autoimmune diseases, and asthma. It is caused by the dysfunction of
KATs and KDACs which interlink different signaling pathways that affect cellular processes
[71]. Some effects of acetylation and its involvement in diseases is given below:

•

Neurodegenerative Diseases
As mentioned earlier, acetylation is known to play a significant role in Alzheimer’s

disease. Studies have proven that acetylated tau protein is prone to aggregation and accumulation
as the lysine residues assigned for ubiquitination are blocked, thereby preventing proteasomal
degradation of aggregated proteins. Subsequently, microtubule assembly was also inhibited
causing damage and leading to tauopathies [77]. Even in the case of schizophrenia, epigenetic
modifications of histone acetylation have been observed [78].

•

Cancer
Research shows that mutations or aberration in KATs and KDACs expression could lead

to cancer development and therefore inhibitors of KATs and KDACs are being tested to treat
cancers. It has also been recognized that acetylation profiles vary with different cell types in the
same species and in cancer, depending on the type, these proteins can either behave as tumor
promoters or tumor suppressors. Acetylation leading to cancers target transcriptional factors and
are generally overexpressed. Myc, which is a family of proto-oncogenes that code for
transcription factors, is also over expressed in cancers and is targeted for acetylation by a number
of KATs. Similar mechanisms are also monitored in other tumor promoting factors making them
a promising target against cancer. p53 is an important tumor suppressor protein that is acetylated
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at different positions to affect diverse roles including DNA binding, proteasomal degradation,
apoptosis, and cell cycle arrest.

Class I and class II KDACs have been reported in cancer development. Sirtuins, on the
other hand, have been linked to both tumor suppression and promotion. For instance, SIRT1 is
overexpressed in prostate cancer and acute myeloid leukemia and targets tumor cell progression.
Conversely, it plays the role of tumor suppression by deacetylating Myc proteins and thereby
preventing the expression of oncogenes [79].

•

Aging
Aging is a physiological change that results in a gradual decrease in the functional

capacity of an organism. Aberrant acetylation is a hallmark observed in aging. Histone
acetylation plays a critical role in regulating senescence and modulating longevity. Lysine
acetylation on histones at positions H3K27 and H3K9 are observed with senescence. Similarly,
higher acetylation is observed in neuronal immediate early genes, which in turn prevents the
expression of these genes and maintains distinguishing memory. Autophagy dysfunction of
which is also a sign of aging is linked to histone H3 acetylation increase [80].
These studies show the role of acetylation in the functioning of the body, thereby making
it an important target for therapeutics and also, understanding the impact of its regulation could
help in generating better insights for various medical conditions.
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1.3 Genetic Code Expansion

Figure 1.6 An outline of the incorporation of non-canonical amino acids (ncAA) using
genetic code expansion strategy. While the evolved aminoacyl–tRNA synthetase (aaRS)
charges the tRNA with ncAA, the tRNA distinguishes the amber codon for ncAA integration
into the designated site of the protein [81].
There are several limitations to studying PTMs of proteins. The dynamic nature of any
PTM makes it challenging to isolate and characterize it. It also known that PTMs do not occur
independently and also crosstalk with other PTMs on different residues. To learn the association
between different modifications and the role of an individual modification on a specific residue
become difficult. The solution to these setbacks could be in co-translationally incorporating the
modified amino acids into proteins directly. The genetic code expansion strategy is applied in
this project to homogeneously incorporate acetyllysine (AcK) at definite positions and monitor
the effects caused by this modification.
In nature, protein translation process in all living organisms is an interplay among
transfer RNAs (tRNA), aminoacyl-tRNA synthetases (aaRS), messenger RNAs (mRNAs) triplet
codons, and ribosomes. 20 amino acids are coded using the almost universal 61 codons and
employ tRNAs charged with amino acids by aminoacyl-tRNA synthetase enzymes. The protein
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sequence on mRNA is read through base pairing between codons of mRNA and anticodons of
tRNA. The fidelity of decoding genetic material to produce polymers of amino acids depends
majorly on 1) accurate tRNA aminoacylation and 2) precise deciphering of codons and
appropriate translocation of tRNA after the peptide bond formation [82].
To recognize the complete functional potential of diverse amino acids and unravel the
shortcomings that restrict the development of protein applications, expansion of the genetic code
becomes necessary. The ability to engineer and rewire the genetic code to expand the repertoire
of amino acids with novel physical and chemical properties opens a new avenue in synthetic
protein chemistry. With increasing interest to develop designer proteins, underpinning the
translation machinery requires 3 conditions: 1) an orthogonal aaRS/tRNA pair 2) specificity of
aminoacyl–tRNA synthetase (aaRS) to an unnatural amino acid and 3) a blank codon (Figure
1.6). Development of orthogonal translational systems (OTS) introduce the possibilities for
synthesis of biopolymers and materials, other than just L-α-AA configuration, with applications
for immunotherapy, therapeutic peptides, vaccines, etc. [83].

1.3.1 Orthogonal translational systems (OTS)
To develop an evolved orthogonal aaRS-tRNA pair, scientists acquire the system from
other domains of life such as archaea. For instance, TyrRS-tRNA pair from Methanocaldococcus
jannaschii is used in E. coli and other bacteria [84], LeuRS-tRNA pair from E. coli has been
used in eukaryotes [85], and a pyrrolysyl-aaRS-tRNA pair (PylRS-tRNACUA) developed from
mutations of Methanosarcina mazei is adaptable in both E. coli and eukaryotes [86, 87].
The term orthogonality here signifies that the donor tRNA does not serve as a substrate
for endogenous synthetases in the host but is exclusively aminoacylated only by the orthogonal

22

synthetase. The subtle divergence between the orthogonal aaRS-tRNA pairs of the donor
organism and the host help maintain the required orthogonality. This prevents the cross reactivity
of the aaRS-tRNA pair between the organisms [88]. Each ncAA is incorporated in reciprocation
to the non-sense or stop codon at the site of interest. The most successful incorporation happens
when the non-canonical amino acid (ncAA) resembles or mimics a natural amino acid. So far,
pyrrolysyl-tRNA synthetase (PylRS) is the most proficient aaRS for incorporating ncAAs [89,
90] in both prokaryotes and eukaryotes.

1.3.2 Selection of Aminoacyl tRNA synthetases
Selection of a compatible aaRS is crucial and through the required evolution aaRS is
made suitable for the incorporation of ncAA. Conventionally, a large variant library
(approximately 109 variants) consisting of mutations in the active site of the synthetase is created
as the first step. E. coli with the synthetase library and cognate tRNA are cultured with amber
codons at permissible sites and selection is based on positive antibiotic resistance such as
ampicillin, or chloramphenicol.

Figure 1.7 Evolution of aaRS variants developed using MAGE. E. coli is recoded to contain a
chromosomal copy of aaRS for evolution. Negative selection markers and green fluorescence
protein (GFP) are used for screening the variants. In this case, tolC and colicin are used for
negative selection. The selected aaRS variants are assessed for ncAA incorporation at multiple
sites [91].
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In the second step, negative barnase selection is employed. The selected clones showing
antibiotic resistance are transformed with the barnase gene, which on expression is toxic to cells.
Thus in the absence of ncAA in media, clones that incorporate natural amino acids are
annihilated and only the ones which use ncAA survive [92].
To increase efficiency and improve the specificity of aaRS to a variety of ncAAs
multiplex automated genome engineering (MAGE) was used (Figure 1.7). This technique
chromosomally integrates aaRS in organisms comprising positive and negative selection to
generate libraries. Using MAGE, M. jannaschii TyrRS was developed to leverage up to 12
mutational changes in the active site and anticodon binding sides and also prevented gene
expression fluctuations associated with plasmids. Results showed that after the first selection
process and two cell sorting cycles, incorporation of ncAAs at 30 sites of the reporter protein
with approximately 50 mg/L yield was produced. The fidelity of the mutant was more than 95%
for each ncAA at the UAG incorporation sites [91].
Other powerful technologies used to evolve aaRS are Phage-assisted continuous
evolution (PACE) and phage-assisted noncontinuous evolution (PANCE), which utilize
bacteriophage propagation technique [93].
In PACE, random libraries of plasmid mutations are created with a defined mutational
frequency (Figure 1.8). By generating many rounds of evolution, aaRS that are many folds active
and selective are obtained. Combining the mutation and selection cycles, this process evolved
Methanosarcina spp. pyrrolysyl-tRNA synthetase (PylRS) that showed 45 folds improved
enzymatic competence than the wildtype, thereby leading to 9.7 increased yields of protein
containing ncAA [94].
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Figure 1.8 Representation of PACE. Accessory plasmid (AP) and complementary plasmid
(CP) encode for the cognate tRNA and T7 RNAP, respectively. The mutagenesis plasmid (MP)
multiples the rate of evolution through arabinose induction and SP represents the selection phage
[94].
To evolve PylRS further with enhanced selectivity of ncAAs, PANCE was developed.
For an active in vivo focused evolution of aaRS, a simple and accessible use of serial flasks
transfer of the evolving selection phage’ (SP) with the gene of interest was employed. As E. coli
was used as a host cell, the genes in the bacteria were held stable, while the genes in SP were
subjected to continuous evolution [95].
Recently, efforts to expand the diversity of PylRS have been explored by studying
interactions apart from the active site. By examining the remote interactions between tRNAPyl,
the tRNA binding domain of PylRS, it has been found that the flexible loop region of the PylRS
that links the N-terminal and C-terminal domains plays a crucial role in binding regulations.
Therefore, varying lengths of linkers were tested to expand amber suppression efficiencies and
substrate specificity. It was learned that linkers of moderate length modify the PylRS and
tRNAPyl binding and consequently improves the output [96].
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1.3.3 Engineering tRNA
tRNAs are key molecules that are a crucial part of the dynamics of protein translation.
Efficiency of tRNAs to deliver amino acids to ribosomes depend on various factors such as
expression, maturation, structure, and stability. Subsequently, modifications of tRNA are
required to produce ncAA in synthetic biology. Determinants which aid in interactions between
tRNA and aaRS, and binding of elongation factors, and ncAAs will be considered for genetic
code expansion. Mutations are also sometimes made to avoid binding to non-cognate aaRS [97]
or to impose identity to prevent erroneous charging [98].
As stop codons are commonly used to incorporate ncAAs into designer proteins, tRNAs
used in genetic code expansion are the ones with no identity elements in the anticodon region.
This will help making mutations to the anticodon arm in order to recognize the stop codons used.
Biosynthesis of such tRNAs are carried out using E. coli as a model organism. To match the
tRNA sequences in different forms of life, modifications are made accordingly. For example, for
ncAA expression in bacteria, CCA terminal sequence is added to the 3’ end of the tRNA gene
from archaea. Such alterations become mandatory to help expression and recognition in the host
organism [89]. Some expressed tRNAs undergo post-translational modifications [99] and in case
of anomalous tRNA synthesis, they are digested by nucleases present in the cell [100] [101, 102].

1.3.4 OTS in E. coli
For cotranslation of ncAA into proteins, E. coli is the most commonly used organism as it
has a well-studied translational system that is efficient and simple. In most cases stop codons
UAG, UGA, and UAA codons serve as a blank for the addition of ncAA [103]. Stop codons
UAG and UAA are recognized by the Release Factor 1 (RF1) in prokaryotes, while RF2
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recognizes UAA and UGA [104]. Commonly, UAG amber codon is used because of its minimal
occurrence in most organisms when compared to other codons. An evolved orthogonal ribosome
with mutations in the 16S rRNA was developed to function parallelly with the natural ribosome
in the cell [105]. Another approach to enhance the translational system was to replace the
essential genes that have an amber codon with UAA.

1.3.5 Applications of genetic code expansion
Genetic code expansion has been commonly used to analyze structure and function of
different proteins, both in vitro and in vivo. To achieve this, chemical cross linkers and
fluorescent ncAAs’ are used. This technique can also be used as a powerful tool to improve
pharmacological properties of proteins used in therapeutic applications. Antibodies with
improved potency, pharmacokinetics, and safety were synthesized by incorporating pacetylphenylalanine (pAcF) genetically on anti-Her2 antibody and similar methods were
implemented for other antibodies production such as bispecific antibodies or antibodies used in
radioimmunotherapy. The applications of genetic code expansion expanded further for the
synthesis of therapeutic peptides, modified viruses, and therapeutic vaccines [83].
To study lysine acetylation, many genetic code expansion systems have been developed
including the AcK system that was engineered from PylRS. This system has 10-fold increase in
the incorporation efficiency. Our group further optimized the AcK incorporation protocol by
linking AcKRS variant and tRNAPyl for improved amber readthrough up to 70%. Moreover, to
evade the action of deacetylases for various studies, non-deacetylatable AcK analogs have been
used. These include 2-amino-8-oxononanoic acid (KetoK), thio-acetyllysine (TAcK), and
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trifluoro-acetyllysine (TFAcK). Apart from histones, acetylation was also studied in p53, human
peroxiredoxin 1 (hPrX1), GTP-binding protein Ran, and E. coli TyrRS [61].

1.4 Rationale and gap in knowledge
Protein acetylation plays a substantial role in almost all biological processes. The
abnormalities in acetylation patterns can cause diseases such as diabetes, cardiovascular diseases,
cancers, and neurodegenerative disorders. In the recent years, proteomic studies have recognized
the role of lysine acetylation in thousands of eukaryotic proteins which significantly expanded
our knowledge, but the characterization of TCA cycle enzymes in relation to acetylation has not
yet been fully studied. In this project, we aim to understand the role of acetylation on the
enzymes of the TCA cycle and how such modifications could lead to the alterations of enzyme
activity. Regulation of enzyme activities has a huge role to play in either maintaining or
disrupting the homeostasis of the body. Thus, these results could lay the foundation for
understanding the development of different diseases such as cancer and could help advance the
search for its treatment.
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2.1 Abstract
Protein acetylation plays important roles in many biological processes. Malate
dehydrogenase (MDH), a key enzyme in the tricarboxylic acid (TCA) cycle, has been identified
to be acetylated in bacteria by proteomic studies, but no further characterization has been
reported. One challenge for studying protein acetylation is to get purely acetylated proteins at
specific positions. Here we applied the genetic code expansion strategy to site-specifically
incorporate Nε -acetyllysine into MDH. The acetylation of lysine residues in MDH could
enhance its enzyme activity. The Escherichia coli deacetylase CobB could deacetylate acetylated
MDH, while the E. coli acetyltransferase YfiQ cannot acetylate MDH efficiently. Our results
also demonstrated that acetyl CoA or acetyl-phosphate could acetylate MDH chemically in vitro.
Furthermore, the acetylation level of MDH was shown to be affected by carbon sources in the
growth medium.
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2.2 Introduction
The acetylation of lysine residues is one of the most common post-translational
modifications of proteins that regulates diverse cellular functions including DNA-protein
interaction, transcription activity, protein stability, stress response, apoptosis, cellular
differentiation, and energy metabolism [1–13]. The abnormality of acetylation modifications is
associated with diabetes, cardiovascular diseases, cancers, and neurodegenerative disorders [14–
24]. During the last decade, proteomic studies have identified lysine acetylation in thousands of
eukaryotic proteins which significantly expanded our knowledge of protein acetylation [25–27].
Interestingly, protein acetylation in bacteria starts to attract attentions in the last five
years [28–35]. A series of proteomic studies have identified hundreds of bacterial proteins with
lysine acetylation, including metabolic enzymes, stress response proteins, regulator of
chemotaxis, chaperones, as well as transcription and translation factors [36–47]. However, few
studies have been performed to further characterize these acetylated proteins. Take E. coli as an
example, only six proteins with lysine acetylation were studied, including acetyl CoA synthetase
[48–51]; CheY, the regulator of bacterial chemotaxis [52–54]; RcsB, the regulator of capsule
synthesis [55–57]; RNase R [58], N-hydroxyarylamine O-acetyltransferase [59], and α-subunit of
RNA polymerase [60, 61]. One challenge for studying lysine acetylation is that it is difficult to
synthesize purely acetylated proteins at specific sites by most classic methods. To solve this
problem, the genetic code expansion strategy has been applied. Rather than adding acetyl group
after protein translation, this approach uses an orthogonal pair of an engineered pyrrolysyl-tRNA
synthetase variant and its cognate tRNA from Methanosarcinaceae species to co-translationally
direct the incorporation of Nε -acetyllysine (AcK) in response to a stop codon at desired positions
in target proteins [62–65].
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MDH, a widely distributed enzyme catalyzing the conversion of oxaloacetate and malate,
plays key roles in many important metabolic pathways including the tricarboxylic acid (TCA)
cycle, glyoxylate bypass, amino acid synthesis, gluconeogenesis, and the exchange of
metabolites between cytoplasm and subcellular organelles [66, 67]. Previous studies have shown
that the acetylation of lysine residues in mammalian MDHs is involved in the crosstalk
mechanisms between adipogenesis and the intracellular energy level [68–70]. However, the
acetylation of bacterial MDH has not been characterized before. Here, we applied the genetic
code expansion strategy to study the lysine acetylation of MDH in E. coli. We also used the same
strategy to study human MDH as comparison.

2.3 Materials and Methods
2.3.1 General molecular biology
The amino acids in this study were purchased from Sigma-Aldrich or ChemImpex.
TOP10 cells (Life Technologies) were used for general cloning. All the cloning experiments
were performed by using the Gibson Assembly kit (New England Biolabs). The mutations of
stop codons in MDH genes were made by the QuikChange II mutagenesis kit (Agilent
Technologies). The strains and plasmids used in this study is listed in Table S1. Western Blots:
The purified MDHs and their variants were fractionated by SDS-PAGE and transferred onto a
PVDF membrane (Bio-Rad). The membrane was incubated at room temperature with gentle
shacking in TTBS and 5% Milk blocking buffer for 60 minutes. The primary antibody, HRPconjugated-Acetylated-Lysine (Ac-K2 -100) Rabbit mAb (Cell Signaling Technology), was
diluted 1:1000 and soaked the membranes overnight at 4℃ degree. The membrane was prepared
for detection using Western Lighting Plus-ECL (PerkinElmer, Inc.). The E. coli proteins
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including CobB and 25 GNAT family acetyltransferases were purified from the ASKA strain
collection by following the purification protocols [97]. The human SIRT3 was purchased from
Sigma-Aldrich (St. Louis, MO, USA). The gene deletion in E. coli was performed by
recombination as previous protocols [98].

2.3.2 Expression and purification of AcK-containing MDH variants
The genes of MDHs and their variants were cloned into the pET15b or pBAD plasmid
with a C-terminal His6-tag and transformed into BL21 (DE3) or Top 10 cells together with the
pTech plasmids harboring the AcK incorporation system for expression. For human MDH2
expression, the predicted mitochondrial targeting sequence (residues 2–24) was removed. The
expression strain was grown on 1 L of LB medium supplemented with 100 μg/mL ampicillin and
50 μg/mL chloramphenicol at 37°C to an absorbance of 0.6–0.8 at 600 nm and protein
expression was induced by the addition of 1 mM IPTG and supplemented with 5 mM AcK and
20 mM nicotinamine (NAM, deacetylases inhibitor). Cells were incubated at 30°C for an
additional 8 h and harvested by centrifugation at 5000 × g for 10 min at 4°C. The cell paste was
suspended in 15 mL of lysis buffer (50 mM Tris (pH 7.5), 300 mM NaCl, 20 mM imidazole, 20
mM NAM) and broken by sonication. The crude extract was centrifuged at 20,000 × g for 30
minutes at 4°C. The soluble fraction was loaded onto a column containing 2 mL of Ni-NTA resin
(Qiagen) previously equilibrated with 20 mL lysis buffer. The column was washed with 50 mL
lysis buffer. The protein bound to the column was then eluted with 2 mL of 50 mM Tris (pH
7.5), 300 mM NaCl, 150 mM imidazole. The purified protein was dialyzed with 50 mM Tris (pH
7.5), 50 mM NaCl, 1mM DTT and 50% glycerol, and stored at −80°C for further studies.
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2.3.3 MDH enzyme assays
The assays were performed by following the instruction of the EnzyChromTM Malate
Dehydrogenase Assay Kit (EMDH-100) from BioAssay Systems. This non-radioactive,
colorimetric MDH assay is based on the reduction of the tetrazolium salt MTT in a NADHcoupled enzymatic reaction to a reduced form of MTT which exhibits an absorption maximum at
565 nm. The increase in absorbance at 565 nm is proportional to the enzyme activity.

2.3.4 LC-MS/MS analyses
The proteins were trypsin digested by a standard in-gel digestion protocol and analyzed
by LC-MS/MS on an LTQ Orbitrap XL (Thermo Scientific) equipped with a nanoACQUITY
UPLC system (Waters). A Symmetry C18 trap column (180 μm × 20 mm; Waters) and a
nanoACQUITY UPLC column (1.7 μm, 100 μm × 250 mm, 35°C) were used for peptide
separation. Trapping was done at 15 μL min−1, 99% buffer A (water with 0.1% formic acid) for 1
min. Peptide separation was performed at 300 nL min−1 with buffer A and buffer B (CH3CN
containing 0.1% formic acid). The linear gradient (51 min) was from 5% buffer B to 50% B at 50
min, to 85% B at 51 min. MS data were acquired in the Orbitrap with one microscan, and a
maximum inject time of 900 ms followed by data-dependent MS/MS acquisitions in the ion trap
(through collision induced dissociation, CID). The Mascot search algorithm was used to search
for the appropriate noncanonical substitution (Matrix Science, Boston, MA).
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2.3.5 In vitro acetylation
The reaction was performed in the buffer containing 50 mM Tris-HCl (pH 8.0), 0.1 mM
EDTA, 10% glycerol, 1 mM DTT and 10 mM sodium butyrate. The acetylation was carried out
by adding 10 μg MDHs, 10 μg of candidate acetyltransferase, and 0.2 mM acetyl CoA in a
volume of 100 μL. Reaction mixtures were completely mixed and incubated at 37 °C.

2.3.6 CobB-mediated in vitro deacetylation
The reaction was performed in buffer contains 40 mM HEPES (pH 7.0), 6 mM MgCl2,
1.0 mM NAD+, 1 mM DTT and 10 % glycerol. 10 μg MDHs, 10 μg CobB, and the reaction
buffer were incubated at 37 °C in a total volume of 100 μL.

2.4 Results
2.4.1 Selecting acetylation sites in MDHs
Recently, several proteomic studies have identified lysine acetylation in E. coli MDH
(eMDH), and lysine residues K99 and K140 were identified to be acetylated in all of these
reports [37–39, 46, 47]. So, we chose these two positions to incorporate AcK. In human cells,
there are two MDH isozymes, the cytosol MDH1 and mitochondrial MDH2 [71]. Human MDH2
(hMDH2) has higher homology to eMDH than hMDH1 does [72].
Previous proteomic studies showed that hMDH2 has four lysine residues acetylated at
positions K185, K301, K307, and K314 [73]. So, we also chose these four positions to
incorporate AcK as comparison. Interestingly, the alignment of eMDH and hMDH2 showed
different patterns: the acetylation sites in eMDH are at the middle part of the primary sequence,
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while those in hMDH2 are mainly at the C-terminus (Figure 2.S1). The acetylation site K185 in
hMDH2 has its counterpart in eMDH at position K162 which was also selected to incorporate
AcK as a control.

Figure 2.1 AcK incorporation into MDHs. A) SDS-PAGE and western blotting analyses of
purified MDHs and their variants. Lane 1, wild-type eMDH; lane 2, eMDH 99AcK; lane 3,
eMDH 140AcK; lane 4, eMDH 162AcK; lane 5; wild-type hMDH2; lane 6, hMDH2 185 AcK;
lane 7, hMDH2 301AcK; lane 8, hMDH2 307AcK; lane 9, hMDH2 314AcK. The same amounts
of proteins were loaded. B) The enzyme activities of MDHs and their acetylated variants. The
activities of wild-type E. coli MDH and human MDH2 were set as 1, respectively. The mean
values and standard errors were calculated based on three replicates.

2.4.2 Site-specifically incorporating lysine acetylation
We incorporated AcK at selected positions mentioned above in both eMDH and hMDH2
by our recently optimized AcK incorporation system which has an optimized tRNAPyl with better
binding with E. coli elongation factor (EF-Tu), thus increasing the incorporation efficiency [65].
The AcK was genetically encoded by an amber stop codon (TAG) which was introduced by site-
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directed mutagenesis. Previous studies showed that the K12-derived strains have substantially
higher acetylation than B-strain-derived BL21 cells during growth [39]. To lower the
background of non-specific acetylation at other lysine residues, we used BL21 (DE3) strain as
the expression host. The incorporation of AcK was confirmed by both western blotting (Figure
2.1A) and mass spectrometry (MS) (Figure 2.S2–2.S8).

2.4.3 The lysine acetylation of MDH increases its enzyme activities
The enzyme activities of eMDH and hMDH2 as well as their acetylated variants were
measured (Figure 2.1B). For eMDH, the acetylation at positions K99 and K140 increased the
enzyme activity by 2.3 and 3.4 folds, individually, which is consistent with our previous study
[65], while the acetylation at the position K162 had little effect. Our previous study also showed
that doubly acetylated eMDH at both positions K99 and K140 had 6-fold higher enzyme activity
than that of wild-type eMDH [65]. For hMDH2, only the acetylation at the position K307
increased the enzyme activity by 3.9 folds, while others had no obvious effects.
Steady-state kinetic analyses were performed with wild-type MDHs and their acetylated
variants (Table 2.1). The lysine acetylation appeared not to affect the KM values of both
substrates, NAD+ and malate, indicating that the increase of enzyme activities results mainly
from the improvement of the overall turnover.
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Table 2.1 Kinetic analyses of MDHs and acetylated variantsa

a

The mean values and standard errors were calculated based on three replicates. The parameters
were determined by nonlinear regression with software GraFit (Erithacus Software).

2.4.4 CobB can deacetylate acetylated MDHs at specific positions
Lysine deacetylases remove the N-acetyl amide moieties and can be broadly divided into
two families according to their reaction mechanism: hydrolytic deacetylases and NAD+dependent deacetylases which are also named as sirtuins [32, 74]. The CobB protein, a sirtuin
family member, was found in many bacteria including E. coli and Salmonella [48, 51]. Recently,
YcgC has been confirmed to be a hydrolytic deacetylase and target a distinct set of substrates
from E. coli CobB, representing a novel family of prokaryotic deacetylases [75].
To determine the deacetylation activity of the CobB protein on acetylated MDHs, K12derived E. coli TOP10 strain with higher acetylation levels was used for in vivo tests [39]. The
genes of eMDH and hMDH2 with C-terminal His6-tags were expressed and purified in wild-type
or ΔcobB cells, individually. Western blotting was used for detecting the acetylation (Figure
2.2A). The deletion of cobB gene increased the acetylation levels of both eMDH and hMDH2,
indicating that CobB could deacetylate their lysine acetylation in vivo. We also measured the
enzyme activities of MDHs from wild-type or ΔcobB cells (Figure 2.2B). The MDHs purified
from ΔcobB cells had higher enzyme activities, which was consistent with the western blotting
results as lysine acetylation could increase MDH activities.
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Figure 2.2 CobB deacetylates MDH. A) Western blotting of purified MDHs from TOP10 and
TOP10 ΔcobB cells. Lane 1 and 4 were from wild-type TOP10 cells. Lane 2 and 5 were from
TOP10 ΔcobB cells. Lane 3 was from TOP10 ΔcobB ΔyfiQ cells. The same amounts of proteins
were loaded. B) The enzyme activities of purified MDHs from TOP10 and TOP10 ΔcobB cells.
The activity of eMDH purified from wild-type TOP10 cells was set as 1. The mean values and
standard errors were calculated based on three replicates. C) Western blotting of acetylated MDH
variants treated with the CobB protein. The acetylation levels of MDH variants after 2-hour
incubation were compared with those without CobB treatment. The same amounts of proteins
were loaded.
We also performed in vitro deacetylation experiments. The optimized AcK incorporation
system mentioned above was used to generate site-specially acetylated eMDH at positions K99,
K140, and K162, individually, and acetylated hMDH2s at positions K185, K301, K307, and
K314, respectively. All these MDH variants were treated with CobB protein separately. Western
blotting was used for detecting the acetylation (Figure 2.2C). Our results showed that CobB was
specific for positions K140 and K162 of eMDH and the position K307 of hMDH2. After 2-hour
treatment of CobB, no detectable acetylation was observed for these three positions by western
blotting, while the acetylation at other positions were not changed obviously. The insensitivity of
acetyl-K99 in eMDH against CobB supports the conclusion from previous studies that although
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CobB is the predominate deacetylase in E. coli, it could not deacetylate the majority of
acetylation at lysine residues [39, 46, 76]. For hMDH2 acetylated variants, we also tested them
with the counterpart of CobB in human, SIRT3, which is the major protein deacetylase in
mitochondria [77]. Similarly, SIRT3 is only specific for acetyl-K307 of hMDH2 (Figure 2.S9).

2.4.5 The acetylation of MDHs
The acetylation of lysine residues is catalyzed by acetyltransferases which can be
categorized into five families: the Gcn5-related N-acetyltransferase (GNAT) family, the MYST
family, the CBP/p300 co-activators, the SRC family of co-activators, and the TAFII group of
transcription factors [78–81]. YfiQ, a member of GNAT family, is the only known
acetyltransferase in E. coli, required for glucose-dependent acetylation of several lysine residues
within RNA polymerase [58] and for the acetylation of Lys544 in RNase R [61].
To determine the acetylation activity of the YfiQ protein on eMDH, TOP10 strain (a
K12- derivated strain with a higher acetylation level) was used for in vivo tests. The gene of
eMDH with a C-terminal His6-tag was expressed in TOP10 ΔcobB ΔyfiQ cells and purified.
Western blotting was used for detecting the acetylation. Compared with the eMDH which was
expressed from TOP10 ΔcobB cells (Figure 2.2A), the deletion of yfiQ gene did not decrease the
acetylation level of eMDH with the ΔcobB background, indicating that the YfiQ protein is not
the major acetyltransferase for eMDH in vivo. We also measured the enzyme activity of eMDH
from TOP10 ΔcobB ΔyfiQ cells (Figure 2.3A). eMDH purified from ΔcobB ΔyfiQ cells had a
similar enzyme activity with eMDH purified from ΔcobB cells, indicating they had similar levels
of acetylation which was consistent with the western blotting results.
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Figure 2.3 Acetylation of E. coli MDH. A) The enzyme activities of purified eMDHs from
TOP10, TOP10 ΔcobB, and TOP10 ΔcobB ΔyfiQ cells. The activity of eMDH purified from
TOP10 cells was set as 1. The mean values and standard errors were calculated based on three
replicates. B) Western blotting of purified eMDH from BL21(DE3) treated with the YfiQ protein
and acetyl CoA for 2 hours. The same amounts of proteins were loaded. C) B) Western blotting
of purified eMDH from BL21(DE3) treated with acetyl CoA or acetyl-phosphate (AcP) for 2
hours and 12 hours, respectively. The same amounts of proteins were loaded.
We also performed in vitro acetylation experiments. The wild type eMDH expressed and
purified from BL21 (DE3) cells which had no detectable acetylation with western blotting
(Figure 2.1B) was treated with purified YfiQ protein and the acetylation donor, acetyl CoA.
Incubated with YfiQ and acetyl CoA for 2 hours, the acetylation level of eMDH had no obvious
difference with that incubated with acetyl CoA only, indicating that YfiQ cannot acetylate
eMDH efficiently in vitro (Figure 2.3B).
Besides YfiQ, there are 24 members of GNAT family acetyltransferases in E. coli, 12
with known substrates: ArgA, AstA, CitC, MnaT, PanM, PhnO, RimI, RimJ, RimL, SpeG,
TmcA, and WecD; the other 12 proteins with unknown functions: ElaA, YafP, YedL, YhbS,
YhhY, YiaC, YiiD, YjaB, YjdJ, YjgM, YjhQ, and YpeA [33]. We tested their functions in
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acetylating eMDH in vitro. Similarly, incubated with individual candidate acetyltransferase and
acetyl CoA for 2 hours, the acetylation level of eMDH had no obvious difference with that
incubated with acetyl CoA only (Figure 2.S10). Previous studies showed chemical acetylation of
proteins both in vitro and in vivo [39, 46, 82–85]. We also noticed that eMDH was acetylated
after incubation with only acetyl CoA for 2 hours (Figure 2.3B). So, we determined the chemical
acetylation of eMDH by acetyl CoA or acetyl-phosphate, respectively. eMDH expressed and
purified from BL21(DE3) cells which has no detectable acetylation was used. Western blotting
was used to detect the acetylation (Figure 2.3C). The results showed that both acetyl CoA and
acetyl-phosphate could chemically acetylate eMDH at a dose-dependent manner. And the
acetylation level of eMDH increased with the incubation time, which is consistent with the
previous study on protein acetylation dynamics [47]. Such acetylation accumulation may also
result from a carbon-to-nitrogen or a carbon-to-magnesium imbalance in vivo [39, 86].

2.4.6 Acetylation of eMDH with different carbon sources
Previous studies showed that the acetylation level of metabolic enzymes is higher when
cells grow with glucose [73]. So, we determined the acetylation level of eMDH purified from
TOP10 cells grown with different carbon sources. Clearly, glucose could increase the acetylation
level of eMDH with a dose-dependent manner (Figure 2.4A). We also measured the enzyme
activities of eMDH from cells with different carbon sources, and it was consistent with the
western blotting results (Figure 2.4B). These results are consistence with previous proteomic
studies [47], indicating the possible role of enzyme acetylation in mediating cellular adaptation
to different environments.

49

Figure 2.4 Acetylation of E. coli MDH with different carbon sources. A) Western blotting of
purified eMDHs from TOP10 cells grown with different carbon sources. LB medium, minimal
medium with different glucose (Glu) concentrations (5%, 2%, 1%, or 0.5%) were used. The
same amounts of proteins were loaded. B) The enzyme activities of purified eMDHs from
TOP10 cells grown with different carbon sources. The activity of eMDH purified from TOP10
cells grown with LB medium was set as 1. The mean values and standard errors were calculated
based on three replicates.

2.5 Discussion
Classic approaches use amino acid substitutions to map functional lysine acetylation
sites. The substitution with arginine retains a positive charge which is often utilized as a
nonacetylated mimic, while the substitution with glutamine abolishes the positive charge which
can act as a surrogate of acetylation [87–89]. However, such strategies sometimes do not reveal
the real effects of lysine acetylation [90]. Here, we synthesized homogenously acetylated
proteins at specific sites by the genetic code expansion strategy to determine the effects of
acetylation directly, overcoming the potential problems with the substitution approach.
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Our kinetic analysis of MDH variants indicated that the catalytic efficiency of acetylated
MDHs increased 2.3 to 3.4 folds (Table 2.1). The KM values of both substrates, NAD+ and
malate, did not change obviously, indicating that acetylation at these positions do not affect the
substrate binding. The results also showed that the human enzyme has higher catalytic efficiency
and much better binding of malate than those of the E. coli enzyme.
Based on the crystal structures on eMDH (PDB ID: 1EMD) and hMDH2 (PDB ID:
2DFD) [91], we mapped the selected acetylated residues used in this study (Figure 2.5). None of
these acetylated sites are at substrate binding sites. It is consistent with our kinetic analyses
which indicated that the lysine acetylation does not affect the substrates binding (Table 1). Our
results also showed that CobB deacetylase was specific for positions K140 and K162 of eMDH
and the position K307 of hMDH2 (Figure 2.2C). From the structures of MDHs (Figure 2.5), we
found that these three residues are located at coiled structures. Lysine residues at position K99 in
eMDH, positions K301 and K314 in hMDH2 are within either helical structures or sheet
structures. These results suggested CobB favors unstructured protein domains which is consistent
with previous studies [39, 46, 76, 92]. Interestingly, as a counterpart of eMDH position K162,
the lysine acetylation at position K185 (at a coiled structure) in hMDH2 is resistant to the
deacetylase (Figure 2.2C), indicating that the specificity of the deacetylase may also depend on
primary sequence contexts, which has been proposed in the previous study [76]. And this
difference may be an ideal target for antibacterial agent development.
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Figure 2.5 Mapping of acetylation sites on the crystal structures of MDHs. The crystal
structures of eMDH (PDB ID: 1EMD) and hMDH2 (PDB ID: 2DFD) were demonstrated with
the selected acetylation sites in this study labelled.
Based on the bioinformatical analyses, there are 25 putative GNAT family
acetyltransferases in E. coli [78]. Some members perform Nα-acetylation such as RimL [93],
while some members are specific for free amino acids like ArgA [94]. There are reports to
describe the functions of only 13 GNAT members, leaving the other 12 members completely
unknown [95]. Although some works have been done to identify the protein motifs which are
recognized by protein acetyltransferases [95, 96], the difference between GNAT members may
be important for their specificities for different protein substrates, thus it is necessary to
characterize those 25 GNAT members for protein acetylation studies as we did in this study
(Figure 2.S10).
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3.1 Abstract
The Escherichia coli isocitrate dehydrogenase (ICDH) is one of the tricarboxylic acid
cycle enzymes, playing key roles in energy production and carbon flux regulation. E. coli ICDH
was the first bacterial enzyme shown to be regulated by reversible phosphorylation. However,
the effect of lysine acetylation on E. coli ICDH, which has no sequence similarity with its
counterparts in eukaryotes, is still unclear. Based on previous studies of E. coli acetylome and
ICDH crystal structures, eight lysine residues were selected for mutational and kinetic analyses.
They were replaced with acetyllysine by the genetic code expansion strategy or substituted with
glutamine as a classic approach. Although acetylation decreased the overall ICDH activity, its
effects were different site by site. Deacetylation tests demonstrated that the CobB deacetylase
could deacetylate ICDH both in vivo and in vitro, but CobB was only specific for lysine residues
at the protein surface. On the other hand, ICDH could be acetylated by acetyl-phosphate
chemically in vitro. And in vivo acetylation tests indicated that the acetylation level of ICDH was
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correlated with the amounts of intracellular acetyl-phosphate. This study nicely complements
previous proteomic studies to provide direct biochemical evidence for ICDH acetylation.
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3.2 Introduction
The family of isocitrate dehydrogenases (ICDHs) catalyzes the reaction of converting
isocitrate to α-ketoglutarate and carbon dioxide in two steps: the oxidation of isocitrate to the
intermediate oxalosuccinate and the decarboxylation of its β-carboxyl group to αketoglutarate
[1]. Depending on the electron acceptor, ICDHs have two distinct classes: NAD+-dependent
ICDHs (EC 1.1.1.41) and NADP+-dependent ICDHs (EC 1.1.1.42) [2, 3]. In human cells, NAD+dependent ICDH3 is located at the mitochondrial matrix and plays the role in energy production
through the tricarboxylic acid (TCA) cycle, while NADP+- dependent ICDH1 and ICDH2 are
found in the cytosol and the mitochondria respectively, shuttling electrons between the cytosol
and the mitochondria [4]. Due to the important role in generating NADPH for cellular defense
against oxidative damage, NADP+-dependent ICDHs have been identified to be associated with a
number of serious human diseases such as cancer and leukemia [5, 6]. Different from eukaryotic
cells, Escherichia coli only has the NADP+-dependent form of ICDH [7, 8], which plays both
roles in generating energy through the TCA cycle and producing NADPH to protect cells from
oxidative damage.
E. coli ICDH has been known to be regulated by phosphorylation for more than 30 years
[9, 10]. The phosphorylated serine residue at position 113 completely inactivates the enzyme,
while dephosphorylation restores the impaired activity [11]. Such reversible phosphorylation is
catalyzed by a single enzyme, the bifunctional ICDH kinase/phosphatase, which is essential for
E. coli growth on acetate as sole carbon source [12]. Since isocitrate is the common substrate of
ICDH in the TCA cycle for energy production and the isocitrate lyase (ICL) in the glyoxylate
shunt for biosynthetic intermediate generation, regulation of ICDH is critical in controlling the
ratio of carbon destined for cell growth and energy production [13– 15]
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As another widely distributed post-translational modification in nature, reversible
acetylation of lysine residues is essential for a wide range of biological processes such as gene
expression, energy metabolism, and cell signaling. Although first identified and well-studied in
eukaryotic cells, more and more evidence has indicated that lysine acetylation is also involved in
a number of prokaryotic cellular functions [16–30]. Interestingly, proteomic studies have
demonstrated that metabolic enzymes including ICDHs are favorable targets for lysine
acetylation in both eukaryotes and prokaryotes [31]. Previous studies of eukaryotic NADP+dependent mitochondrial ICDH2 showed that it is regulated by lysine acetylation for defending
reactive oxygen species under calorie restriction [32, 33]. However, E. coli ICDH has no
sequence identity with eukaryotic ICDH2, so the effect of lysine acetylation on E. coli ICDH still
remains unclear. Recently, we have characterized lysine acetylation of another TCA cycle
enzyme, malate dehydrogenase (MDH) in E. coli [34]. Our results showed that lysine acetylation
could increase the MDH activity and was regulated by the CobB deacetylase and intracellular
acetyl-phosphate, as well as the carbon source in growth media. In this study, our results
demonstrated that lysine acetylation of ICDH has distinct effects but also shares common
features with the acetylation of MDH. To our best knowledge, this is the first biochemical
characterization of lysine acetylation of bacterial type NADP+-dependent ICDH.

3.3 Materials and Methods
3.3.1 General molecular biology
Chemical compounds in this study were purchased from Sigma-Aldrich, VWR
International, or Chem-Impex International. DH5α cells were used for general cloning.
Polymerase chain reaction (PCR) reactions and plasmid constructions were performed by using
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the NEBuilder HiFi DNA Assembly Kit (New England Biolabs). Point mutations of the icd gene
in the plasmid were made by the Q5 Site-Directed Mutagenesis Kit (New England Biolabs).
Inactivation of genes from the E. coli genome was performed by the recombination approach
[82]. The strains and plasmids used in this study is listed in Table 3.3.S1. CobB, YcgC, RutR,
RcsB, and YfiQ proteins were expressed from the ASKA collection and purified by previous
protocols [83].
Protein concentrations were measured by the Bradford Protein Assay (Bio-Rad). The
purified ICDH and its variants were fractionated on a 4–20% SDS-PAGE gel and visualized by
the Bio-Safe Coomassie Stain (Bio-Rad). For western blotting, the fractionated SDSPAGE gel
was transferred onto a PVDF membrane by using the Trans-Blot Turbo Transfer System (BioRad). The PVDF membrane was incubated at room temperature with gentle shacking in the
blocking buffer (5% bovine serum albumin, 0.1% Tween 20 in Tris-buffered saline) for 2 h. The
horseradish peroxidase (HRP)-conjugated acetyllysine (AcK) antibody (Cell Signaling
Technology) was diluted 1:1000 with the blocking buffer and soaked the blocked PVDF
membrane overnight at 4 °C. The membrane was prepared for chemiluminescence detection by
using Pierce ECL Western Blotting substrates (Thermo Scientific).

3.3.2 Expression and purification of acetylated ICDH variants
The protocols followed previous studies with slightly modifications [54]. The genes of
the ICDH and its variants were cloned into the pCDF-1b plasmid (EMD Millipore) with a Cterminal His6-tag, and transformed into BL21 (DE3) cells (New England Biolabs) together with
the pTech plasmids harboring the AcK incorporation system for expression [56, 84]. The
expression strain was grown on 500 mL of LB medium supplemented with 100 μg/mL
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streptomycin and 50 μg/mL chloramphenicol at 37°C to an absorbance of 0.6–0.8 at 600 nm.
Then protein expression was induced by the addition of 0.1 mM Isopropyl β-D-1thiogalactopyranoside (IPTG). For AcK-containing protein expression, media were additionally
supplemented with 10 mM AcK and 20 mM nicotinamine (NAM). Cells were incubated at 25°C
for an additional 12 h and harvested by centrifugation at 3200 × g for 15 min at 4 °C. The cell
paste was suspended in 12 mL of lysis buffer [50 mM Tris (pH 7.8), 300 mM NaCl, 20 mM
imidazole, 20 mM NAM, and 5 mM β-mercaptoethanol with cocktail protease inhibitors
(Roche), and broken by sonication. The crude extract was centrifuged at 18,000 × g for 20 min at
4°C. The soluble fraction was filtered through a 0.45-μm membrane and loaded onto a column
containing 2 mL of Ni-NTA resin (Qiagen) previously equilibrated with 20 mL lysis buffer. The
column was then washed with 20 mL of washing buffer [50 mM Tris (pH 7.8), 300 mM NaCl,
and 40 mM imidazole]. The protein bound to the column was finally eluted with 2 mL of elution
buffer [50 mM Tris (pH 7.8), 300 mM NaCl, and 150 mM imidazole]. The purified protein was
dialyzed with 2 L of storage buffer [25 mM Tris (pH 7.8), 10 mM NaCl, 1 mM dithiothreitol
(DTT), and 50% glycerol], and stored at −80°C.

3.3.3 The ICDH enzyme assay and kinetic analyses
The enzyme activity assay followed the previous protocol [85]. The reaction was
performed in the buffer containing 25 mM MOPS, 100 mM NaCl, 5 mM MgCl2, and 1 mM DTT
at 25°C. The reaction was carried out by mixing 30 ng ICDH or its variants, 1 mM isocitrate, and
1 mM NADP+ in a total volume of 100 μL. The rates of reaction were determined by monitoring
the production of NADPH at 340 nm. For kinetic analyses, the concentration of one substrate
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was varied while the other substrate was at a fixed concentration of 5 mM. The kinetic
parameters were calculated from nonlinear regression by software Grafit (Erithacus Software).

3.3.4 Mass spectrometry (MS) analyses
The full-length MS analyses were performed by the University of Arkansas Statewide
Mass Spectrometry Facility, following the previous protocol [79]. Purified proteins were
dialyzed with pure water, diluted to 0.05 mg/mL, and analyzed by a Bruker UltraflexII TOFTOF with a MALDI ionization source. Spectra were obtained in the positive ion, linear mode.
The LC-MS/MS analyses were performed by Yale University Keck Proteomics Facility,
following previous protocols [86, 87]. Proteins were digested in gel by trypsin and analyzed by
LC-MS/MS on an LTQ Orbitrap XL equipped with a nanoACQUITY UPLC system. The
Mascot search algorithm was used to search for the appropriate noncanonical substitution.

3.3.5 The in vitro acetylation assays
The acetylation assay was modified from previous experiments [83]. The reaction was
performed in the buffer containing 50 mM Tris (pH 7.8), 0.1 mM EDTA, 10% glycerol, 1 mM
DTT and 10 mM sodium butyrate. The acetylation was carried out by mixing 10 μg ICDH, 10 μg
of YfiQ, 0.2 mM acetyl CoA in a total volume of 100 μL and incubated at 37°C for 2 hours. For
non-enzymatic acetylation, 10 μg ICDH was incubated with varying concentrations of acetylphosphate at 37°C for different time spans.
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3.3.6 The in vitro deacetylation assays
The deacetylation reaction was slightly modified from the previous study [88]. The
reaction was performed in buffer contains 40 mM HEPES (pH 7.0), 6 mM MgCl2, 1.0 mM
NAD+, 1 mM DTT and 10 % glycerol. The deacetylation was carried out by mixing 10 μg
acetylated ICDH variants, 10 μg CobB or YcgC proteins in a total volume of 100 μL and
incubated at 37°C for 2 hours.

3.4 Results
3.4.1 Site-specifically incorporating lysine acetylation into ICDH
Proteomic studies of E. coli have identified totally more than 20 lysine residues to be
acetylated in ICDH [35–44]. However, the sets of acetylation sites from these studies are distinct
from each other, mostly because of the differences in E. coli strains, growth conditions,
acetylated peptide detection methods, and mass spectrometry resolutions. Thus, we chose lysine
residues for later studies based on both proteomic [35–44] and structural studies [45–52] by three
criteria: 1) those that have been identified in more than four independent proteomic studies; 2)
those that are located at the active site or subunit interfaces; 3) those that are conserved among
different organisms. Based on these standards, eight lysine residues (K55, K100, K142, K177,
K230, K235, K242, and K350) were selected. Among them, only K100 has not been identified to
be acetylated before, but it was reported to be succinylated instead [44, 53]. We chose it as a
control because of its essential role in catalysis and substrate binding [52].
Then we applied the genetic code expansion approach to incorporate AcK directly into
those selected positions by our recently optimized protocol individually [54]. This approach
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utilizes an engineered Methanosarcina barkeri pyrrolysyl-tRNA synthetase [55] and an
optimized cognate tRNApyl [56] to read through the TAG stop codon in the gene of ICDH
introduced by site-directed mutagenesis as AcK, thus producing homogeneously acetylated
ICDH variants at selected sites [57, 58]. To reduce the background of non-specific acetylation at
other lysine residues, we used the BL21 (DE3) strain as the expression host which was shown to
have significantly lower levels of protein acetylation than E. coli K12-derived strains [37].
Indeed, the wild-type ICDH purified from BL21 (DE3) cells had no detectable acetylation by
western blotting, while site-specifically acetylated ICDH variants all had clear bands against the
AcK antibody (Figure 3.1a). Mass spectrometry (MS) analyses confirmed that the incorporation
of AcK was at selected positions respectively (Figure 3.S1–3.S9).

Figure 3.1 The effect of acetylation at single lysine residues. a) SDS-PAGE and western
blotting analyses of purified ICDH and its variants. Lane 1, wild-type ICDH; lane 2, ICDH55AcK; lane 3, ICDH-100AcK; lane 4, ICDH-142AcK; lane 5; ICDH-177AcK; lane 6, ICDH230AcK; lane 7, ICDH-235AcK; lane 8, ICDH-242AcK; lane 9, ICDH-350AcK. The same
amounts of proteins were loaded. b) Relative enzyme activities of ICDH and its variants with
acetyllysine (AcK) or glutamine (Gln) substitution. The activity of wild-type E. coli ICDH was
set as 1. Mean values and standard deviations were calculated based on three biological
replicates
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3.4.2 Determining the effect of lysine acetylation on the ICDH activity
The enzyme activities of ICDH and its acetylated variants were measured (Figure 3.1b).
The effect of acetylation on the enzyme activity was different site by site. Acetylation at K55 or
K350 significantly increased the activity, while acetylation at K142, K177, or K242 only had
small enhancement. On the other hand, acetylation at K235 lost about 40% of the activity, while
acetylation at K100 or K230 almost completely eliminated the enzyme activity.
As a classic approach, glutamine is commonly used as a mimic of acetylated lysine.
Thus, we also substituted selected lysine residues with glutamine respectively, and measured the
activities of those K-to-Q variants as a comparison with the direct AcK incorporation approach.
Interestingly, the results from glutamine substitution were quite different from those by direct
acetyllysine incorporation (Figure 3.1b). Substituting lysine with glutamine decreased enzyme
activities at all tested positions. Glutamine substitution at K100 or K230 abolished the enzyme
completely which was similar to the AcK incorporation approach but results for other positions
were quite different from two approaches. For example, replacement of K55 by glutamine
decreased the enzyme activity dramatically, but direct incorporation of acetyllysine at K55
significantly increased the activity (Figure 3.1b).
To illustrate how acetylation affects the enzyme activity, steady-state kinetic analyses
were performed for the wild-type ICDH and its acetylated variants (Table 3.1). Acetylation at
K55 or K350 increased the turnover number, while acetylation at K142, K177, or K242 had no
significant effects on kinetic parameters. On the other hand, acetylation at K100 decreased the
catalytic efficiency by 106 -fold, consistent with the previous study in which K100 was replaced
with Met, Gln, or His [52]. Acetylation at K230 dramatically decreased both the turnover
number and the affinity of isocitrate which aligned with previous mutagenesis studies on ICDH
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[49, 59], while acetylation of K235 halved the turnover number without affecting binding of both
substrates.
Table 3.1 Kinetic analyses of ICDH and its acetylated variants

The mean values and standard deviations were calculated based on three biological replicates.
For KM determination, one substrate was varied with six different concentrations, while the other
substrate was fixed at a concentration of 5 mM. The parameters were determined by nonlinear
regression with software GraFit (Erithacus Software).
Proteomic studies indicated that E. coli ICDH could be multiply acetylated
simultaneously [35–44], so possible cooperative effects of multiple lysine acetylation on ICDH
were tested. Starting with simpler cases, we applied the genetic code expansion strategy to
incorporate AcK at two sites of selected lysine residues simultaneously. As a representative,
K55, of which acetylation increased the enzyme activity significantly, was chosen to be
acetylated in all variants. Totally seven dual-acetylated ICDH variants were generated (ICDH55AcK/100AcK, ICDH-55AcK/142AcK, ICDH-55AcK/177AcK, ICDH-55AcK/230AcK,
ICDH-55AcK/235AcK, ICDH-55AcK/242AcK, and ICDH-55AcK/ 350AcK). Both western
blotting and mass spectrometry analyses confirmed the simultaneous incorporation of AcK at
selected positions (Figure 3.2a, Figure 3.S10– 3.S17). Then we measured the enzyme activities
of these dual-acetylated variants (Figure 3.2b). However, the improving effect of acetylation at
K55 could not recover impaired activities caused by acetylation at K100 and K230, implying
their essential roles in catalysis or substrate binding.
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Figure 3.2 The effect of simultaneous acetylation at two lysine residues. a) SDS-PAGE and
western blotting analyses of purified ICDH and its variants. Lane 1, wild-type ICDH; lane 2,
ICDH-55AcK/100AcK; lane 3, ICDH-55AcK/142AcK; lane 4, ICDH-55AcK/177AcK; lane 5;
ICDH-55AcK/230AcK; lane 6, ICDH-55AcK/235AcK; lane 7, ICDH-55AcK/242AcK; lane 8,
ICDH-55AcK/350AcK. The same amounts of proteins were loaded. b) Relative enzyme
activities of ICDH and its variants with acetyllysine (AcK) at two lysine sites simultaneously.
The activity of wild-type E. coli ICDH was set as 1. Mean values and standard deviations were
calculated based on three biological replicates.
Due to the existence of endogenous deacetylases in cells, lysine residues usually are not
acetylated completely. Thus, besides above in vitro experiments in which lysine residues were
homogeneously acetylated, we also performed in vivo studies which could reflect the real
situation in living cells. The E. coli K12-derived BW25113 strain was used for all in vivo
experiments in this study (unless indicated). Firstly, we compared the acetylation levels of ICDH
purified from BW25113 cells grown in LB media or M9 media with 0.2% glucose. Cells were
grown at 37°C for 8 hours after inoculation. The native ICDH was purified by the established
protocol with 50 mM nicotinamine (the deacetylase inhibitor) in all purification buffers [60]. The
acetylation of purified ICDHs was determined by western blotting (Figure 3.3a). ICDH purified

71

from LB media had no detectable acetylation, while that from glucose media had a clear band,
indicating glucose could induce the acetylation of ICDH in vivo, which is consistent with
previous proteomic studies [37, 41, 43]. Then we measured their enzyme activities (Figure 3.3b).
ICDH purified from glucose media with a higher acetylation level lost about 60% of the activity
compared to that from LB media. We were not surprised at these results, because our in vitro
experiments above showed that the acetylation at key residues such as K100 and K230 almost
impaired the enzyme activity completely which could not be recovered by acetylation at other
positions even those like K55 of which acetylation could increase the enzyme activity (Figure
3.2b).

Figure 3.3 The effect of acetylation on ICDH in vivo. a) SDS-PAGE and western blotting of
purified ICDHs from LB media (lane 1) and M9 media with 0.2% glucose (lane 2). The same
amounts of proteins were loaded. b) The enzyme activities of purified ICDHs from LB media
and M9 media with 0.2% glucose. The activity of ICDH purified from LB media was set as 1.
The mean values and standard deviations were calculated based on three biological replicates.
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3.4.3 Deacetylation of ICDH
The acetyl on the ε-amino group of lysine residues is Table 3.1, and its removal needs a
category of enzymes called lysine deacetylases [61, 62]. Till now, there are only two known
lysine deacetylases identified in E. coli: the CobB protein, a NAD+-dependent sirtuin class
deacetylase [63–65], and the YcgC protein, a NAD+-independent serine hydrolase family
member with a distinct set of substrates from CobB [66].

Figure 3.4 Deacetylation of ICDH. a) SDS-PAGE and western blotting of purified ICDHs from
wild-type BW25113 (lane 1), BW25113 ΔycgC (lane 2), and BW25113 ΔcobB (lane 3). b)
Western blotting of site-specifically acetylated ICDH variants treated with CobB for 2 hours. c)
Western blotting of site-specifically acetylated ICDH variants treated with YcgC for 2 hours.
The same amounts of proteins were loaded in all the experiments. d) Relative enzyme activities
of ICDH and its acetylated variants after treatment with CobB or YcgC. The activity of wildtype E. coli ICDH without deacetylase treatment was set as 1. Mean values and standard
deviations were calculated based on three biological replicates.
To determine the deacetylation of ICDH by CobB and YcgC, the acetylation levels of
native ICDHs purified from wild-type, ΔycgC, and ΔcobB of BW25113 cells grown in M9 media
with 0.2% glucose were compared by western blotting (Figure 3.4a). The deletion of cobB
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increased the acetylation level of ICDH, consistent with previous quantitative proteomic studies
[39–42], while inactivation of ycgC had no obvious effect.
A previous study showed that inactivation of the cobB gene increased the acetylphosphate concentration in cells [39], and acetyl-phosphate could increase protein acetylation
globally [37, 41]. Thus, although the deletion of the cobB gene increased the acetylation level of
ICDH (Figure 3.4a), we cannot conclude that CobB can deacetylate ICDH directly. To provide
direct evidence, we performed in vitro deacetylation experiments. The site-specifically acetylated
ICDH variants generated by the genetic code expansion strategy were treated with the purified
CobB protein, respectively. Western blotting was used for detecting the acetylation (Figure
3.4b). The results showed that CobB was only specific for position 55, 142, 177, or 350. After 2hour treatment of CobB, no detectable acetylation was observed for these positions by western
blotting, while acetylation at other positions were not changed obviously, which could explain
the detectable acetylation with an intact cobB gene in wildtype BW25113 cells (Figure 3.3a).
Those selected lysine residues were mapped onto the crystal structure of ICDH [46] (Figure
3.S18). CobB-sensitive sites (K44, K142, K177, and K350) are all located at ICDH surfaces,
while CobB-resistant sites (K100, K230, K235, and K242) are internal and close to the active
site. Although the CobB substrate specificity is varied by different criterions, a common feature
is to be located at protein surfaces [37, 42]. The same in vitro deacetylation experiments were
performed for the YcgC protein (Figure 3.4c). Consistent with in vivo experiments, no significant
changes were observed after 2-hour treatment of YcgC at all sites tested. RutR, the known
substrate of YcgC [66], was used as a positive control to show that YcgC was active in this study
(Figure 3.S19). We also performed enzyme assays to measure the activities of those sitespecifically acetylated ICDH variants after CobB and YcgC treatment (Figure 3.4d). Treatment
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of the variant acetylated at position 55, 142, 177, or 350 with the CobB protein decreased its
activity to the level of wild-type enzyme, consistent with above western blotting results which
showed that CobB was specific for those sites.

3.4.4 The acetylation of ICDH
Currently, it is believed that lysine acetylation in E. coli has two major mechanisms: the
acetyl CoA-dependent enzymatic process and the acetyl-phosphate-dependent chemical reaction
[16–22]. YfiQ is the only known protein acetyltransferase in E. coli which belongs to the Gcn5related N-acetyltransferase family [67, 68]. To determine the acetylation of ICDH by YfiQ, the
acetylation levels of native ICDHs purified from wild-type, ΔyfiQ, ΔcobB, and ΔyfiQ ΔcobB of
BW25113 cells grown in M9 media with 0.2% glucose were compared by western blotting
(Figure 3.5a). The deletion of yfiQ did not decrease the acetylation level of ICDH expressed in
cells with or without the ΔcobB background, indicating that ICDH is not the substrate of YfiQ in
vivo, which is consistent with data from proteomic studies [37, 40–42]. To provide direct
evidence, we also performed in vitro acetylation experiments. The wild-type ICDH expressed
and purified from BL21 (DE3) cells was treated with purified YifQ and 0.2 mM acetyl CoA.
After 2-hour incubation, ICDH had no detectable acetylation, indicating that ICDH is not the
substrate of YfiQ in vitro either (Figure 3.S20).
Then, we tested the chemical acetylation by acetyl-phosphate alone in vitro. The wildtype ICDH expressed and purified from BL21 (DE3) cells was treated with acetyl-phosphate at
concentrations of 200 μM, 3 mM, and 12 mM, corresponding to estimated intracellular acetylphosphate concentrations at the exponential phase, the stationary phase, and the ΔackA
background which accumulates acetyl-phosphate, respectively [37, 69, 70]. Western blotting was
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used to determine acetylation levels (Figure 3.5b). Clearly, acetyl-phosphate could chemically
acetylate ICDH in both dose- and time-dependent manners in vitro which aligned with proteomic
studies [37, 41, 43]. The acetyl-phosphate-treated ICDH was then analyzed by LC-MS/MS to
determine acetylated lysine sites. Besides the eight selected sites in above in vitro studies, we
identified additionally acetylated lysine residues at positions 4, 20, 47, 73, 166, 174, 265, 273,
278, 378, and 387 (Figure 3.S21–S31). Most of them are located at the protein surface which is
consistent with the specificity of acetyl-phosphatedependent acetylation [41, 43]. But we did not
detect acetylation at positions 12, 58, 186, 199, 267, and 401 which have been reported by
proteomic studies before [31]. Although this could result from differences in strains, growth
conditions, and mass spectrometry resolutions, it also indicates that acetylation at those sites may
need additional cofactors, coenzymes, or unknown protein acetyltransferases.
Reversely, among those acetylated lysine residues detected in in vitro acetylation
experiments, K47, K73, and K278 as well as K100 have never been identified to be acetylated in
any proteomic studies before, indicating the differences between the in vitro study and the in vivo
process. Thus, we performed in vivo tests for acetyl-phosphatedependent acetylation of ICDH.
Acetyl-phosphate is the intermediate of the phosphotransacetylase (Pta) – acetate kinase (AckA)
pathway [71]. Pta catalyzes the reversible conversion between acetyl CoA and acetyl-phosphate,
while AckA catalyzes the reversible conversion between acetate and acetyl-phosphate. When
cells are grown in media without using acetate as carbon source, inactivation of pta will block
the acetyl-phosphate production, while ΔackA accumulates acetyl-phosphate [71]. The
acetylation levels of native ICDHs purified from wild-type, Δpta, and ΔackA of BW25113 cells
grown in M9 media with 0.2% glucose were compared by western blotting (Figure 3.5c). As
expected, acetylation of ICDH was correlated with intracellular concentrations of acetyl-
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phosphate. ΔackA increased the acetylation level of ICDH which is consistent with proteomic
studies [37, 41]. Although our in vitro studies demonstrated that acetyl-phosphate could acetylate
ICDH without any enzymes, we could not exclude the existence of specific protein
acetyltransferases for ICDH acetylation in vivo because of the different sets of acetylated lysine
residues detected by in vitro and in vivo approaches.

Figure 3.5 Acetylation of ICDH. a) SDS-PAGE and western blotting analyses of purified
ICDHs from BW25113 wild-type (lane 1), ΔyfiQ (lane 2), ΔcobB (lane 3), and
ΔyfiQ ΔcobB (lane 4). b) SDS-PAGE and western blotting analyses of purified ICDH treated
with different concentrations of acetyl-phosphate (AcP). C) SDS-PAGE and western blotting
analyses of purified ICDHs from wild-type BW25113 (lane 1), Δpta (lane 2), and ΔackA (lane 3).
The same amounts of proteins were loaded in all the experiments.
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3.5 Discussion
By site-specifically incorporating acetyllysine into selected lysine positions, we provided
direct biochemical evidence for the effect of acetylation on ICDH site by site. Besides the key
residues K100 and K230 in catalysis and substrate binding which have already been
characterized by mutational, kinetic, and structural studies before [46, 49, 50, 52, 59], we also
showed that acetylation of K55 and K350 could increase the activity (Figure 3.1a) which is
totally unknown before. Although crystal structures of the ICDH K55AcK and ICDH K350AcK
variants are needed to demonstrate the mechanism in detail, we could still use existing ICDH
crystal structures to propose acetylation effects (Figure 3.6). K350 is located at the entrance of
the active site and is close to the substrate NADP+. Although K350 does not contact with NADP+
directly, the removal of the positive charge of the lysine side chain may facilitate NADP+ binding
as shown in the kinetic analysis (Table 3.3.1). On the other hand, K55 is located at the back side
of the active site, but it interacts with three hydrophobic residues (L375, I413, and M416) in two
helices which form part of the active site. Acetylation neutralizes the positive charge of K55 side
chain, thus facilitating its interactions with those hydrophobic side chains which may induce
conformational changes to improve the catalysis.
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Figure 3.6 Mapping of K55 and K350 on the ICDH structure. K55 and K350 were mapped
on the structure of the ICDH dimer (PDB ID: 4aj3). Two subunits were colored with red and
green separately. Only the side chains of labelled residues were shown.
During growth of E. coli on acetate, the glyoxylate shunt pathway bypasses two steps in
the TCA cycle, generating succinate, malate, and free coenzyme A from isocitrate to replenish
central metabolism with biosynthetic precursors [72]. The first enzyme in the glyoxylate bypass,
isocitrate lyase (ICL), is the direct competitor of ICDH for isocitrate. The partition of carbon flux
between ICDH and ICL at the junction of isocitrate is well controlled to balance energy
production and cell growth in different growth stages and conditions [14, 15, 73]. As the first
prokaryotic enzyme known to be regulated by phosphorylation, ICDH has been well studied on
its regulation by the bifunctional ICDH kinase/phosphatase [9, 12, 74]. ICL was also shown to be
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phosphorylated at a histidine residue [75–77], but it is more sensitive to the concentration of
isocitrate in cells [14, 15, 73]. Interestingly, Both ICDH and ICL are acetylated at multiple lysine
residues which could be induced by glucose in growth media [37, 40, 41, 43]. A previous study
showed that ICL activity decreased with acetylation [40]. And our study here indicated that
acetylation could also impair the ICDH activity (Figure 3.3b). However, the net effect of lysine
acetylation on dividing isocitrate into two pathways needs to be determined in future studies.
Another open question is whether phosphorylation and acetylation have crosstalk for
regulating ICDH and IDL for the carbon flux partition. Firstly, proteomic data showed that the
bifunctional ICDH kinase/phosphatase is also acetylated at multiple lysine residues [31], but
these acetylation targets have not been confirmed and further characterized. Secondly, the
acetylation of ICDH may affect its own phosphorylation, since many acetylated lysine residues
studied in this work are located close to S113 which is the key residue for reversible
phosphorylation [51, 78]. And our recently developed genetic incorporation system for
simultaneous acetylation and phosphorylation could be a useful tool to answer these questions
[79].
Because of the easy handling, glutamine has been widely used as a mimic of acetylated
lysine to study effects of acetylation on protein structures, functions, and interactions. However,
the difference between the structures of glutamine and acetyllysine could be easily ignored. The
length of glutamine side chain is about 6 Å, while that of acetyllysine is approximately 10.5 Å.
Such difference could cause unexpected results [80, 81]. Indeed, in this study, we showed that
the classic glutamine mutagenesis method and the genetic acetyllysine incorporation approach
provided opposite results in some cases such as acetylation at K55 of ICDH (Figure 3.1b).
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4.1 Abstract
The citrate synthase (CS) catalyzes the first reaction of the tricarboxylic acid cycle,
playing an important role in central metabolism. The acetylation of lysine residues in the
Escherichia coli Type II CS has been identified at multiple sites by proteomic studies, but their
effects remain unknown. In this study, we applied the genetic code expansion strategy to
generate 10 site-specifically acetylated CS variants which have been identified in nature.
Enzyme assays and kinetic analyses showed that lysine acetylation could decrease the overall CS
enzyme activity, largely due to the acetylation of K295 which impaired the binding of acetylcoenzyme A. Further genetic studies as well as in vitro acetylation and deacetylation assays were
performed to explore the acetylation and deacetylation processes of the CS, which indicated that
the CS could be acetylated by acetyl-phosphate chemically and be deacetylated by the CobB
deacetylase
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4.2 Introduction
The citrate synthase (CS) (EC 2.3.3.1) catalyzes the reaction of condensing acetyl CoA
with oxaloacetate (OAA) to form citrate and CoA by three steps: enolization of the thioester
group of acetyl CoA, condensation of the enolate anion with OAA, and hydrolysis of the citrylthioester [1]. This step is not only the first reaction of the tricarboxylic acid (TCA) cycle for
central metabolism but also a key step in amino acid biosynthesis, thus the CS can be found in
almost all living organisms. Although catalyzing the same reaction, there are two types of CSs in
nature [2]. Type I CSs are found in eukaryotes, archaea, and Gram-positive bacteria. They form
homodimers with the active site located between two independently folded domains, which are
partially closed by induced fit upon substrate binding [3]. On the other hand, Type II CSs are
only found in Gram-negative bacteria, and share highly identical amino acid sequences with
Type I CSs [4]. Although the Type II CS forms a hexamer rather than a dimer, it could be
considered as a trimer of homodimers with similar structures of Type I CS dimers [3].
Besides structures, the regulation of CSs by NADH has also been well studied. It was
found that the Type II CS from Escherichia coli was specifically and strongly inhibited by
NADH with an allosteric mechanism, and such inhibition could be alleviated by high salt or
basic conditions [5]. Later, the crystal structure of the E. coli Type II CS demonstrated that the
NADH binding site was close to the dimer–dimer interface [6]. Since Type I CSs are
homodimers, they cannot form the NADH-binding site, which explains the insensitivity of Type
I CSs to NADH. It was proposed that Type II CSs were evolved from Type I CSs by building
new contact surfaces for dimers and the regulatory site for NADH binding [6]. It should be noted
that the NADH-dependent allosteric mechanism is not found in all Type II CSs. For example, the
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CS from Acetobacter aceti also forms a hexamer, but cannot be inhibited by NADH, possibly
due to the missing of key residues for NADH binding [7].
Recently, it has been shown that the eukaryotic Type I CS could be regulated by lysine
acetylation. SIRT3, a deacetylase, was shown to deacetylate and increase CS activity [8].
Although firstly discovered and extensively studied in eukaryotic histones and transcriptionassociated factors, lysine acetylation is also known to play important roles in bacterial
physiology [9–12]. Acetylome studies have identified multiple lysine acetylation sites in the E.
coli Type II CS [13], but their functions are still unknown. Our group has studied the lysine
acetylation of two TCA cycle enzymes, malate dehydrogenase (MDH) and isocitrate
dehydrogenase (ICDH) and showed that lysine acetylation had different effects on these two
TCA enzymes [14,15]. In this study, we characterized lysine acetylation of the E. coli Type II CS
and explored its modification processes.

4.3 Materials and Methods
4.3.1 General molecular biology
General molecular biology chemicals and bacterial growth media were purchased from
Sigma-Aldrich (St. Louis, MO, USA), VWR International (Radnor, PA, USA), or Chem-Impex
International (Wood Dale, IL, USA). Plasmid were constructed by following the protocol of the
NEBuilder HiFi DNA Assembly Kit (New England Biolabs, Ipswich, MA, USA). Point
mutations of the gltA gene were generated by following the protocol of the Q5 Site-Directed
Mutagenesis Kit (New England Biolabs). Strains and plasmids used in this study are listed in
Table 4.S1.
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Protein concentrations were determined by the Bradford Protein Assay (Bio-Rad,
Hercules, CA, USA). For western blotting, purified CS and its variants were fractionated on a 4–
20% SDS-PAGE gel and transferred to the PVDF membrane. The horseradish peroxidase
(HRP)-conjugated acetyllysine (AcK) antibody (Cell Signaling Technology, Danvers, MA,
USA) was used as the primary antibody, and chemiluminescence was detected by using Pierce
ECL Western Blotting substrates (Thermo Scientific, Waltham, MA, USA).

4.3.2 Expression and purification of acetylated CS variants
Wild-type CS and its variants were expressed from the pCDF-1b plasmid (EMD
Millipore, Burlington, MA, USA) with a C-terminal His6-tag in BL21 (DE3) cells (New England
Biolabs). The protocols of purification were described in previous studies with slightly
modifications [28]. The expression strain was grown in LB medium. The protein expression was
induced by 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when cell grew to OD600 nm
0.6. For AcK-containing protein expression, media were additionally supplemented with 10 mM
AcK and 20 mM nicotinamine (NAM). Cells were incubated at 30 °C for an additional 4 h and
harvested by centrifugation. Cells were broken by sonication in 12 mL of lysis buffer [50 mM
Tris (pH 7.8), 300 mM NaCl, 20 mM imidazole, 20 mM NAM, and 5 mM β-mercaptoethanol
with cocktail protease inhibitors (Roche, Basel, Switzerland). The crude extract was centrifuged
at 18,000 x g for 20 min at 4 °C. The soluble fraction was filtered through a 0.45-µm membrane
and loaded onto a column containing 2 mL of Ni-NTA resin (Qiagen, Hilden, Germany)
previously equilibrated with 20 mL lysis buffer. The column was then washed with 20 mL of
washing buffer [50 mM Tris (pH 7.8), 300 mM NaCl, and 40 mM imidazole], and then eluted
with 2 mL of elution buffer [50 mM Tris (pH 7.8), 300 mM NaCl, and 150 mM imidazole]. For
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storage, the purified protein was dialyzed with 2 L of 25 mM Tris (pH 7.8), 10 mM NaCl, 1 mM
dithiothreitol, and 50% glycerol, and stored at 80 °C.

4.3.3 The CS enzyme assay and kinetic analyses
The enzyme activity assay was performed by following the previous protocol. It is based
on the reaction of CoASH with Ellman’s reagent DTNB (5,5-dithio-bis-(2-nitrobenzoic acid)),
which has the absorbance at 412 nm. The reaction was performed in the buffer containing 20
mM Tris (pH7.8), 1 mM EDTA, 0.1 M KCl, 0.1 mM DTNB, 0.1 mM OAA, 0.1 mM acetyl CoA,
and 50 ng CS or its variants at 25°C. The kinetic parameters were determined from nonlinear
regression (Erithacus Software, East Grinstead, UK) by varying the concentration of one
substrate while the other substrate concentration was fixed.

4.3.4 Mass spectrometry analyses
The full-length MS analyses were performed by following the previous protocol [40].
Purified proteins were diluted to 0.05 mg.mL-1 with purified water, and then analyzed by
MALDI-TOF. The LC-MS/MS analyses were performed by following the previous protocol
[41]. Proteins were digested in gel by trypsin and analyzed by LC-MS/MS on an LTQ Orbitrap
XL equipped with a nanoACQUITY UPLC system. The Mascot search algorithm was used to
search for the substitution of the lysine residue with AcK.
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4.3.5 The in vitro acetylation assays
The acetylation assay was performed by following the protocol described in the previous
study [42]. The reaction was performed in the acetylation buffer [50 mM HEPES (pH 7.0), 0.1
mM EDTA, 10% glycerol, 1 mM DTT, and 10 mM sodium butyrate]. The acetylation reaction
was initiated by mixing 10 µg CS, 10 µg of YfiQ, 0.2 mM acetyl CoA, or varied concentrations
of AcP in a total volume of 100 µL, and then incubated at 37 °C for 1 h.

4.3.6 The in vitro deacetylation assays
The deacetylation assay was performed by following the protocol described in the
previous study [43]. The reaction was performed in the deacetylation buffer [50 mM HEPES (pH
7.0), 5 mM MgCl2, 1.0 mM NAD+, 1mM DTT, and 10% glycerol]. The deacetylation reaction
was initiated by mixing 10 µg acetylated CS variants, 10 µg CobB proteins in a total volume of
100 µL and incubated at 37 °C for 1 h.

4.4 Results
4.4.1 Generating site-specifically acetylated CS variants
To explore the impact of acetylation on the E. coli CS, we first studied the site-specific
effects of those acetylation events, which could provide direct biochemical evidence for CS
acetylation. To avoid biased selection, we chose all the lysine residues that have been identified
to be acetylated in nature by at least two independent acetylome studies, which were K38, K168,
K283, K295, K310, K328, K356, K405, K418, and K422.
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Site-directed mutagenesis of lysine to glutamine has been used commonly to study
protein acetylation. However, our previous study showed that such method sometimes could
draw opposite conclusions with those derived from the approach of direct incorporation of
acetyllysine (AcK) [15]. So, in this study, we utilized an optimized system to produce purely
acetylated CS variants at specific sites listed above by the genetic code expansion strategy
individually [27]. To lower the background of nonspecific acetylation for in vitro assays, we
used the BL21(DE3) strain as the host, which has much lower acetylation levels than E. coli K12
strains [18]. Indeed, the wild-type CS overexpressed in BL21(DE3) cells had no detectable
acetylation (Figure 4.1), consistent with our previous studies on MDH and ICD which also
showed that wild-type MDH and ICD purified from BL21(DE3) cells had no detectable
acetylation [14,15].

Figure 4.1. The incorporation of AcK at individual lysine sites of the CS. SDS/PAGE and
western blotting analyses of purified CS and its variants from BL21(DE3) cells. Lane 1, wildtype CS; lane 2, CS38AcK; lane 3, CS-168AcK; lane 4, CS-283AcK; lane 5; CS-295AcK; lane
6, CS-310AcK; lane 7, CS-328AcK; lane 8, CS-356AcK; lane 9, CS-405AcK; lane 10, CS418AcK; lane 11, CS-422AcK. The same amounts of proteins were loaded. Anti-AcK:
acetyllysine antibody.
To facilitate the purification process and remove truncated proteins due to the usage of
the UAG stop codon as the signal for AcK incorporation, we fused a His6-tag to the C terminus
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of the CS. In this case, only site-specifically acetylated CS variants which had AcK at the
position corresponding to the UAG stop codon could have the His6- tag and were able to be
purified by affinity chromatography, while early terminated proteins had no such tags and were
washed away during purification. Indeed, all the site-specifically acetylated CS variants had clear
single bands and their acetylation were detected by the AcK antibody (Figure 4.1). The purity
and sites of AcK incorporation were confirmed with full length MS and LC-MS/MS analyses,
respectively (Figures 4.S1–4.S11).

4.4.2 Characterizing the impact of lysine acetylation on the CS activity
Under the standard CS enzyme assay condition containing 0.1 M KCl, enzyme activities of
the wild-type CS and its site-specifically acetylated variants were measured (Figure 4.2A).
Except for K283 (P = 0.0005) and K295 (P < 0.0001), all other variants did not have
significantly different activities with that of the wild-type CS. Interestingly, acetylation at K283
increased the activity by nearly twofold, while acetylation at K295 decreased the activity by
about 10-fold. Since acetylation could occur at multiple lysine residues in the same protein, we
also generated a dual-acetylated variant at K283 and K295 simultaneously by the genetic code
expansion strategy [28], which still had a significant activity loss (P < 0.0001), implying the key
role of acetylation at K295 in regulating CS enzyme activities. To exclude the possibility that the
decreased activity was caused by mis-folding of the acetylated variant, we performed circular
dichroism (CD) analysis of the CS-295AcK variant. The CD spectrum of the variant was highly
similar to that of the wild-type CS, indicating that AcK incorporation did not affect the proper
folding of the enzyme, and the activity loss should be caused by the impact of acetylation on the
CS directly (Figure 4.S17).
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To further study the effect of lysine acetylation at K283 and K295 on CS activities,
steady-state kinetic analyses were performed (Table 4.1). Clearly, the binding of acetyl CoA was
the major cause for activity changes. Acetylation of K283 facilitated the acetyl CoA binding,
while acetylation of K295 impaired the binding of acetyl CoA.

Figure 4.2 Characterization of the CS and its acetylated variants. (A) Relative enzyme
activities. The activity of the wild-type (WT) Escherichia coli CS was set as 1. Mean values and
standard deviations were calculated based on three replicates (n = 3). Two-tailed P values were
determined by the t-test, and the significance level is 0.05.
The allosteric inhibition by NADH is a unique feature for the E. coli Type II CS [5]. For
this purpose, NADH inhibition tests were performed on those acetylated variants (Table 4.1).
K168 is known to bind NADH directly, so the CS-168AcK variant was included in the test as a
control. Indeed, the CS-283AcK variant had stronger resistance to NADH than the wild-type CS,
which supported our hypothesis. On the other hand, the CS-295AcK variant was still sensitive to
NADH.
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Table 4.1 Steady-state kinetic parameters of the CS and its acetylated variants.

a

Measured with 0.1 M KCl. b Acetyl CoA (AcCoA) was held at 1 mM. c OAA was held at 0.1
mM. d Measured in absence of KCl. e Mean values and standard deviations were calculated based
on three replicates (n = 3). The kinetic parameters were determined by nonlinear regression with
software GRAFIT.
To further study the acetylation of the CS in living cells, we performed in vivo studies.
There were two differences between in vitro and in vivo experiments through this study. First, in
vitro assays used BL21 (DE3) cells which have different acetate metabolism from K12 strains to
express the wild-type CS and its acetylated variants in order to decrease the background of
nonspecific acetylation, while the E. coli K12-derived BW25113 strain was used for in vivo
studies. Second, the wild-type CS and its acetylated variants were overexpressed and fused with
affinity tags for easy purification in in vitro experiments, while the native CS was used to
eliminate possible impacts from affinity tags for all in vivo studies, which was purified by the
established protocol [30]. First, we compared the acetylation levels of native CSs purified from
BW25113 cells grown in the LB medium only and the LB medium with 0.2% glucose. The
acetylation levels of purified native CSs were determined by western blotting (Figure 4.3A).
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Figure 4.3 The effect of acetylation on the CS in vivo. (A) SDS/PAGE and western blotting of
purified native CSs from BW25113 cells growth in the LB medium only or the LB medium with
0.2% glucose (LB+Glc). The same amounts of proteins were loaded. (B) The enzyme activities
of purified native CSs from the LB medium only or the LB medium with 0.2% glucose. The
activity of the CS purified from the LB medium only was set as 1. Mean values and standard
deviations were calculated based on three replicates (n = 3). Two-tailed P values were
determined by the t-test, and the significance level is 0.05.
Clearly, The CS from the LB medium containing glucose had a higher acetylation level
than that from the LB medium only, which was consistent with previous proteomic studies.
Then, we measured enzyme activities of both native CSs. The CS purified from the LB medium
containing glucose lost more than 30%, a significant decrease (P = 0.0111) of the activity
compared to that purified from the LB medium only (Figure 4.3B), which should be caused by
the acetylation of K295 according to in vitro studies above.
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Figure 4.4 Mapping of key lysine residues in CS structures. (A) The crystal structure of the
Escherichia coli CS hexamer (PDB ID: 4G6B) with acetylation sites K283 and K295 labeled.
Two subunits in one dimer were in green and blue separately. Other dimers were in gray. (B)
The crystal structure of the A. aceti CS dimer (PDB ID: 2H12) with K302 (the counterpart of
K295 in E. coli CS) labeled. Two subunits in one dimer were in green and blue separately. The
acetyl CoA analog carboxymethyldethia-CoA was in purple.

4.4.3 Identifying the mechanism of CS acetylation
Next, we studied the acetylation process of the CS in E. coli. It is known that lysine
acetylation in E. coli is generated by either enzymatic acetylation with acetyl CoA as the acetyldonor or nonenzymatic acetylation with acetyl-phosphate (AcP) as the acetyl-donor [11,12]. Till
now, YfiQ is still the only well-known protein acetyltransferase (KAT) in E. coli [31]. Very
recently, a proteomic study has identified four additional KATs (RimI, YiaC, YjaB, and PhnO)
in E. coli. However, overexpression of those four KATs did not increase the acetylation level of
the CS. Thus, we first tested the acetylation of the CS by YfiQ. For in vivo tests, the acetylation
level of the native CS purified from the wild-type or ΔyfiQ of BW25113 cells grown in the
glucose medium was determined by western blotting (Figure 4.5A). The inactivation of the yfiQ
gene did not decrease the acetylation level of the CS, indicating that YfiQ is not responsible for
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CS acetylation. Then, we performed in vitro acetylation assays. Again, the His6- tagged CS was
overexpressed in BL21(DE3) cells for easy purification and a cleaner background of nonspecific
acetylation. The purified CS was then treated with YifQ and 0.2 mM acetyl CoA for 1 h, which
had no detectable acetylation, consistent with in vivo results above (Figure 4.5B).

Figure 4.5 Acetylation of the CS by YfiQ. SDS/ PAGE and western blotting. (A) purified
native CSs from the wild-type, ΔyfiQ, ΔcobB, and ΔyfiQ ΔcobB of BW25113 cells; (B) purified
CS from BL21(DE3) cells treated with purified YfiQ and/or acetyl CoA in vitro. The same
amounts of proteins were loaded.
YfiQ belongs to the Gcn5-related N-acetyltransferase (GNAT) family. Besides YfiQ,
there are 24 more GNAT family members in E. coli including those four recently identified
KATs. Thus, we further tested all these 24 GNATs individually (Figure 4.6). However, none of
them could acetylate the CS in vitro, implying that nonenzymatic acetylation plays the major role
in acetylating the CS.
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Figure 4.6 In vitro acetylation assays of CS with GNATs. SDS/PAGE and western blotting of
purified CS from BL21(DE3) cells which was treated with 24 GNATs and acetyl CoA in vitro,
individually. Lane -1 is purified CS treated with 0.2 mM acetyl CoA in vitro as a background
control. Lane 0 is purified CS treated with 3 mM AcP in vitro as a positive control. Lane 1 to 24
is purified CS treated with 0.2 mM acetyl CoA and ArgA, AstA, CitC, ElaA, MnaT, PanM,
PhnO, RimI, RimJ, RimL, SpeG, TmcA, WecD, YafP, YedL, YhbS, YhhY, YiaC, YiiD, YjaB,
YjdJ, YjhQ, YjgM, and YpeA, respectively.
Thus, we then tested nonenzymatic acetylation of the CS by AcP. For in vivo tests,
BW25113 cells with the deletion of the pta gene or the ackA gene were used. Pta is the
phosphate acetyltransferase, catalyzing the reversible conversion between acetyl CoA and AcP,
thus the Δpta strain has much lower AcP in cells [18,33]. On the other hand, AckA, an acetate
kinase, catalyzes the conversion between acetate and AcP. Inactivation of the ackA gene
accumulates AcP in a non-acetate medium [34]. Native CSs from the wildtype, Δpta, and ΔackA
of BW25113 cells grown in the glucose medium were purified and tested by western blotting
(Figure 4.7A).
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Figure 4.7 Acetylation of the CS by AcP. SDS-PAGE and western blotting. (A) purified
native CSs from the wild-type, Δpta, and ΔackA of BW25113 cells; (B) purified CS from
BL21(DE3) cells treated with AcP in vitro. The same amounts of proteins were loaded.
Clearly, Δpta lowered while ΔackA increased the acetylation level, indicating that CS
acetylation levels were correlated with intracellular AcP concentrations. For in vitro tests, the
wild-type CS overexpressed in BL21 (DE3) cells with a clean acetylation background was
purified and treated with 0.2 mM, 3mM, or 12 mM AcP, which corresponds to estimated
intracellular AcP concentrations at the exponential phase, the stationary phase, or the AcPaccumulating condition (ΔackA), respectively [18,33,35]. Western blotting results indicated that
AcP itself could acetylate CS in dose- and time-dependent manners, supporting in vivo results
above (Figure 4.7B).
Next, we used MS analyses to determine acetylated lysine sites in the CS by the in vitro
AcP-treatment. Besides the 10 lysine residues tested above, five additional positions at K7, K22,
K56, K293, and K333 were also found to be acetylated (Figures 4.S12–4.S16). Among them,
K22 and K333 have never been identified to be acetylated in cells by any E. coli acetylome
studies, possibly because the acetylation at these sites had lower stoichiometry and/or could be
deacetylated easily in cells. Reversely, the acetylation at K10, K105, and K357 of the CS from E.
coli acetylome database was not identified in our in vitro tests. Although this could be caused by
differences in strains, growth conditions, and mass spectrometry resolutions, it also implied the
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possible existence of additional KATs or cofactors needed specifically for these lysine sites in
vivo.

4.4.4 Exploring the mechanism of CS deacetylation
Acetylation of certain lysine residues is a reversible process and could be removed by lysine
deacetylases (KDACs). Although there are many types of KDACs in eukaryotic cells, the CobB
protein, a homolog of sirtuin, is still the only known KDAC in E. coli [37,38]. Thus, we first
tested the deacetylation of the CS by CobB. For in vivo tests, the acetylation levels of native CSs
purified from the wild-type and ΔcobB of BW25113 cells grown in the glucose medium were
compared by western blotting (Figure 4.5A). The deletion of cobB increased the CS acetylation,
indicating that CobB could deacetylate the CS in vivo. We also determined the acetylation level
of the native CS from cells with both genes of yfiQ and cobB inactivated (Figure 4.5A). The
deletion of yfiQ could not decrease the CS acetylation level in the absence of CobB, confirming
that YfiQ is not responsible for CS acetylation.
The in vivo study above could not provide information of the sensitivities of individual
acetylated lysine sites against the CobB deacetylase. Since we could generate site-specifically
acetylated CS variants, we performed in vitro deacetylation experiments for this purpose. Each
site-specifically acetylated CS variants expressed and purified from BL21(DE3) cells were
treated with the purified CobB protein. Western blotting was used to determine their acetylation
levels before and after the treatment (Figure 4.8A).
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Figure 4.8 Deacetylation of the CS. (A) Western blotting of site-specifically acetylated CS
variants treated with CobB in vitro. Numbers are the positions of acetylated lysine residues. The
same amounts of proteins were loaded. (B) Mapping of lysine residues sensitive to CobB; (C)
Mapping of lysine residues resistant to CobB; (D) Mapping of K356 on the crystal structure of
the Escherichia coli CS hexamer (PDB ID: 4G6B). Two subunits in one dimer were in green and
blue separately. Other dimers were in gray. Lysine residues and the mobile loop were marked
with red. In the active form the CS, the mobile loop is proposed to move as the arrow shows.
Most of the lysine sites were sensitive to CobB, but we did observe that three positions
K168, K356, and K405 could resist CobB. Lysine residues tested were mapped onto the crystal
structure of the CS [3]. CobB-sensitive sites (K38, K283, K295, K310, K328, K418, and K422)
are all located at the CS surface (Figure 4.8B), which is a common feature for CobB-sensitive
lysine residues.
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Figure 4.9 The enzyme activities of purified CSs from the LB medium only or the LB
medium with 0.2% glucose before and after 1-h CobB treatment. The activity of CS purified
from the LB medium only was set as 1. Mean values and standard deviations were calculated
based on three replicates (n = 3).
Enzyme assays above showed that the CS activity was decreased by higher acetylation
levels, largely due to the acetylation at K295 (Figures 4.2 and 4.4B). To confirm that the activity
loss was caused by acetylation indeed, we treated the native CS purified from the glucose
medium with the CobB protein, then measured its activity (Figure 4.9). The CS activity was
restored, which could be explained by the fact that K295 is sensitive to CobB (Figure 4.8A), and
the deacetylation of K295 frees the lysine residue for the proper binding with acetyl CoA.

4.5 Discussion
There have been a number of E. coli acetylome studies, but the sets of identified acetylated
lysine residues in the E. coli CS are quite different (from only one site to as many as 11
positions) and not well overlapped, largely due to the differences in strains, growth conditions or
stages, acetylated peptide enrichment approaches, and mass spectrometry (MS) detection
methods and resolutions [16,18,19]. Recently, several quantitative mass spectrometry studies of
acetylation in E. coli have showed that the CS has much higher stoichiometry of acetylation than
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many other E. coli proteins [24–26]. Due to the presence of multiple positions for acetylation, 10
lysine residues were selected based on the criteria mentioned above.
Interestingly, based on the crystal structure of the CS, both K283 and K295 are located in
the ‘mobile loop’ (residues 267–297), which forms part of the acetyl CoA-binding site (Figure
4.3A) [6]. The binding of NADH affects the refolding of the mobile loop to form the acetyl
CoA-binding site. The CS from A. aceti is also a hexamer but is insensitive to NADH [7]. The
counterpart of the mobile loop in the A. aceti CS is highly ordered, which could explain its
resistance to NADH [7]. So, we proposed that the acetylation of K283 could induce the mobile
loop to form a more ordered structure, thus facilitating the acetyl CoA binding. The counterpart
of K295 in the A. aceti CS, K302, directly contacts with acetyl CoA [7] (Figure 4.3B). Thus, the
loss of the enzyme activity in the CS-295AcK variant should be caused by the impaired acetyl
CoA binding, and such loss could not be restored by the acetylation of K283 in the dualacetylated variant CS-238/295AcK (Figure 4.2). Reversely, the higher activity associated with
acetylation of K283 also requires K295 to be unacetylated.
Comparing CSs from different organisms, K295 is well conserved while K283 is not [3].
This is not surprising, as K295 (or its counterpart in the A. aceti CS, K302) directly contacts with
acetyl CoA, while K283 might not be necessary in NADH-resistant CSs to form ordered
structures for acetyl CoA binding (Figure 4.4). Recently, the human Type I CS was also shown
to lose activity with higher acetylation levels [8]. However, the specific acetylation site(s) which
caused such loss was not determined. Based on acetylome database, the counterpart of K295 in
the human CS, K327, has also been identified to be acetylated, which could explain the activity
loss. Thus, besides the overall dimer structures, two types of CSs might also share the regulatory
mechanism by lysine acetylation.
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Also, it has been observed that among the CobB-resistant sites, K168 is at the dimer–
dimer interface for NADH binding, while K405 is located at the subunit–subunit interface of the
dimer (Figure 4.8C). Both residues are not easily accessible for CobB to deacetylate. K356 is
located at the surface of the CS. Besides the possible reason that CobB cannot recognize
acetylated K356, another potential explanation is that the mobile loop does not form the proper
binding site for acetyl CoA in the T state (the inactive form) which was shown in the crystal
structure, while in the R state (the active form), the mobile loop will have a conformational
change, which could bury the K356, thus blocking its contacts with CobB (Figure 4.8D).
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CHAPTER V
CONCLUSION AND FUTURE DIRECTIONS
5.1 Conclusion
The TCA cycle, for long, has been considered an interlink among other metabolic and
regulatory pathways in an organism and the critical role played by this pathway is associated
with the fitness of a cell. Several types of cancers, neurodegenerative disorders, and rare diseases
have been implicated with TCA cycle and correspondingly, this has raised a number of new
questions that lead to insights on the intricate and intertwining role of TCA cycle enzymes on the
maintenance of cellular health for the sound functioning of an organism. In doing so, the critical
role imposed by acetylation on these enzymes becomes imperative. However, the relationship
between the enzymes and acetylation has not been fully explored.
The major research focus of this dissertation was to reveal the consequences of acetylation on
the enzyme activity of TCA cycle enzymes and in turn understand its impacts on the overall
health of an organism. In this dissertation, we investigated the effects of acetylation on malate
dehydrogenase, isocitrate dehydrogenase, and citrate synthase.
To study the effects of acetylation on these enzymes the genetic code expansion strategy was
used to incorporate lysine at specific positions in the protein. The tailor-made proteins were
synthesized by site-directed mutations on the target gene to replace lysine with stop codons for
AcK expression in E. coli. The pyrrolysyl-tRNA synthetase system was further developed
through phage assisted evolution to create an efficient AcKRS system. Using this orthogonal
translation machinery, the co-translation of AcK in desired proteins was made possible.
Our findings from chapter 2 indicate that positions selected for acetylation in malate
dehydrogenase either show increased enzyme activity or remain unaltered with acetylation. The
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increased activity was rendered to the improved turnover of the enzyme and had no effects of the
substrate bindings. CobB, a member of the bacterial situins family was specific to lysine residues
K140 and K162 present on the surface. In human MDH, SIRT3 is functional and was specific to
K307. Since all these positions were present on the unstructured regions of the enzyme, they
were more prone to the action of situins.
In chapter 3, we found that NAD+ dependent isozyme of isocitrate dehydrogenase (IDH3)
takes part in energy production via TCA cycle and undergoes acetylation. Between prokaryotic
and eukaryotic sequences that showed no similarity, 8 lysine residues were selected for
acetylation. In IDH, an exception to the selection criteria was made by choosing K100 which is
normally succinylated. K100 was selected as it is positioned such that it plays a commanding
role in the catalysis and substrate binding of the enzyme. From chapter-1, it is evident that an
enzyme could comprise of lysine residues that can both increase and decrease the enzyme
activity, but the regulatory role of acetylated positions K100 and K230 which cause complete
loss of enzyme activity has a stronger effect. The increase in enzyme activity caused by
acetylation of K55 and K350 were attributed to the positioning of these residues. It can be
deduced that the placement of K55 behind the active site causes its interaction with the other
residues in the helices that form the active site. Similarly, K350 which is present on the entrance
of the active site, due to the cancellation of the positive charge, may facilitate better binding of
NADP+. As in the case of MDH, CobB was successful in deacetylating lysine residues present
on the surface of the enzyme (K55, K142, K177, and K350). In this chapter, an important
comparison was also made between using glutamine as an acetyllysine mimic and the direct
incorporation of AcK into the protein co-translationally. It was inferred that the modulation in
the enzyme activity between the two depended on the position of the residues. In the case of
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position K242, the difference in the enzyme activity between the two methods seemed less but
for residues K55 and K350 the difference in approaches had considerably large variations and
also led to opposite effects in certain cases. This result implied that the use of glutamine as a
mimic for AcK does not always function in the appropriate way and it cannot be used as a
substitute for AcK.
In chapter 4, the role of acetylation on citrate synthase was studied. Of the 10 selected
residues that were acetylated only K283 and K295 showed variations in enzyme activity. The
type II of citrate synthase (CS) undergoes allosteric inhibition with the binding of NADH. These
positions, K283 and K295, are present in the mobile loop of the enzyme thereby facilitating
acetyl CoA binding. Steady state kinetics for CS demonstrates the imposing role of acetyl CoA
binding in causing the variations in enzyme activity. Correspondingly, when NADH binds, the
refolding of mobile loop is affected and in turn, the binding of acetyl CoA. With duel acetylation
incorporation of K283/K295, the regulatory role of K283 overpowers that of K295. This could
also be the reason that K295 is conserved in many organisms while K283 is not. The role of
K283 becomes unnecessary if the loop is well structured. Similar effects are verified in human
CS where acetylation of the enzyme lowers the enzyme activity. This could suggest that the
counterpart of K295 in humans, K327 could be acetylated. The action of CobB sirtuin
deacetylase is different in CS when compared to MDH and IDH, in the sense that it acts on the
residues on the surface with the exception of K356. The positions which are resistant to CobB
are K168 (NADH binding site), K405 (dimer-dimer interface), and K356 (surface). It is
comprehended that when CS is in the T-state or resting state, K356 is exposed to the surface as
in the considered crystal structure (PDB ID: 4G6B) but in the R-state, this residue become buried
in the sequence thereby evading the action of CobB.
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With all the enzymes studied, the impact of glucose on acetylation was verified. It was
observed that with increase in concentration of glucose in the growth media, there was dosedependent increase in the acetylation levels of the enzyme indicating the likely role of
acetylation in facilitating cellular adaptations under varied conditions. This could be one of the
reasons for the difference in acetylation profiles for different cells under diverse conditions of the
same organism.
The acetyl transferases of GNAT family consist of 25 members and interestingly, with
further investigation, results showed that none of the 25 acetyltransferases play a role in the
transfer of acetyl group in MDH, IDH or CS. This could probably be because of the presence of
other unknown acetyl transferases or the non-enzymatic acetyl transfer. Non-enzymatic
acetylation with acetyl phosphate (AcP) revealed that enzymes showed high acetylation levels.
Additionally, several positions which were never reported in acetylome studies were also shown
to be acetylated.

5.2 Significance of This Dissertation
A renewed interest has resulted in understanding the role of TCA cycle in the overall
functioning of an organism. By studying the major modifications of the cycle, we can gain
awareness on the mechanisms that underlie the astonishing spectrum of clinical abnormalities. In
this dissertation, we highlighted a unique technique for the study of acetylation on different
proteins and validated that the use of glutamine as a mimic for AcK is not recommended.
Although many studies have identified acetylation sites across different domains of life for
thousands of proteins, the role of these acetylation sites have not been well understood. As it is
now clear that not all proteins are enzymatically acetylated, it would be vital to identify the
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specificity of different acetyltransferases. We believe that the dynamic process of addition or
removal of acetyl group can also be nutrient dependent, and we expect that these studies will
support future researchers with improved insights on the mechanistic nature of acetylation. With
the understanding gained from this work, a better focus on several disease models can be gained
in the future. For instance, many proteins that are upregulated in various cancers can be
controlled by recognizing which PTM of a specific amino acid could be modulated for this
purpose. This method also paves a path for targeted drug delivery against pathogens which have
their pathogenesis associated to a number of PTMs.

5.3 Future Directions
The insertion of a simple acetyl group can have dramatic effects on the functioning of a
protein. The masking of the positive charge on lysine has been predominantly confirmed in
histones, but non-histone protein acetylation has also been gaining great attention over the years.
A number of such protein modifications are known to be conserved in eukaryotes, thus
suggesting the importance of these amino acids in the functioning of a protein both
biochemically and genetically. Hence, expansion of our knowledge on acetylation in eukaryotes
will be significant.
Additionally, PTMs are dynamic and multiple PTMs can crosstalk to perform a specific role.
In many cases such as autophagy, phosphorylation precedes acetylation for subsequent actions.
Sometimes, several modifications such as acetylation, methylation, and ubiquitination can
compete for a lysine residue. When a given residue is modified it blocks other modifications.
Such conditions are typically established in protein p53. Once the lysine residue is acetylated, it
blocks the interception of both ubiquitination and methylation. There are many such proteins that
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are yet to be explored for such signaling cascades. It will also be useful to develop deeper
insights on acetylation profiles of cells in response to a stimulus in a dynamic manner.
The role of acetylation on mitochondrial proteins is a field that has developed recent attention
and advanced studies have to be undertaken to unravel the full potential of mitochondrial
functions. Furthermore, in today’s world, we are yet to fully encompass the basic biology of
protein acetylation, especially in eukaryotes. Acetylated proteins could serve as biomarkers for
various disease conditions and with the advancing technology it has the potential to aid in the
development of diagnostic, prognostic, and therapeutic tools.
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Supplementary Data
Supplementary Data for Chapter 2
Table 2.S1. The list of strains with plasmids used in this study.
Strain

Plasmid

Top10

pBAD-eMDH

Top10

pBAD-hMDH2

Top10 cobB

pBAD-eMDH

Top10 cobB

pBAD-hMDH2

Top10 cobB patZ

pBAD-eMDH

Top10

pBAD-eMDH(140TAG) + pTech-AcK-OTS*

Top10 cobB

pBAD-eMDH(140TAG) + pTech-AcK-OTS

BL21(DE3)

pET15a-eMDH

BL21(DE3)

pET15a-eMDH(99TAG) + pTech-AcK-OTS

BL21(DE3)

pET15a-eMDH(140TAG) + pTech-AcK-OTS

BL21(DE3)

pET15a-eMDH(162TAG) + pTech-AcK-OTS

BL21(DE3)

pET15a-hMDH2

BL21(DE3)

pET15a-hMDH2(185TAG) + pTech-AcK-OTS

BL21(DE3)

pET15a-hMDH2(301TAG) + pTech-AcK-OTS

BL21(DE3)

pET15a-hMDH2(307TAG) + pTech-AcK-OTS

BL21(DE3)

pET15a-hMDH2(314TAG) + pTech-AcK-OTS

*: OTS is the abbreviation for orthogonal translational modification.
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Figure 2.S1. The alignment of protein sequences of E. coli MDH and human MDH2. The
selected acetylation sites in E. coli MDH are marked by *, and those in human MDH2 are
marked by #.

Figure 2.S2. LC-MS/MS analysis of E. coli MDH 99-AcK. The tandem mass spectrum of the
peptide (residues 88-107) SDLFNVNAGIVK*NLVQQVAK (ion score 79) from purified eMDH
with one amber codon at position 99. K* denotes AcK incorporation. The partial sequence of the
peptide containing the AcK can be read from the annotated b or y ion series.
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Figure 2.S3. LC-MS/MS analysis of E. coli MDH 140-AcK. The tandem mass spectrum of the
peptides (residues 135-153) AGVYDK*NKLFGVTTLDIIR (ion score 45) from purified eMDH
with one amber codon at position 140. K* denotes AcK incorporation. The partial sequence of
the peptide containing the AcK can be read from the annotated b or y ion series.

Figure 2.S4. LC-MS/MS analysis of E. coli MDH 162-AcK. The tandem mass spectrum of the
peptides (residues 154-164) SNTFVAELK*GK (ion score 74) from purified eMDH with one
amber codon at position 162. K* denotes AcK incorporation. The partial sequence of the peptide
containing the AcK can be read from the annotated b or y ion series.
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Figure 2.S5. LC-MS/MS analysis of human MDH2 185-AcK. The tandem mass spectrum of
the peptides (residues 177-191) ANTFVAELK*GLDPAR (ion score 99) from purified hMDH2
with one amber codon at position 185. K* denotes AcK incorporation. The partial sequence of
the peptide containing the AcK can be read from the annotated b or y ion series.

Figure 2.S6. LC-MS/MS analysis of human MDH2 301-AcK. The tandem mass spectrum of
the peptides (residues 298-307) GIEK*NLGIGK (ion score 75) from purified hMDH2 with one
amber codon at position 301. K* denotes AcK incorporation. The partial sequence of the peptide
containing the AcK can be read from the annotated b or y ion series.
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Figure 2.S7. LC-MS/MS analysis of human MDH2 307-AcK. The tandem mass spectrum of
the peptides (residues 302-314) NLGIGK*VSSFEEK (ion score 90) from purified hMDH2 with
one amber codon at position 307. K* denotes AcK incorporation. The partial sequence of the
peptide containing the AcK can be read from the annotated b or y ion series.

Figure 2.S8. LC-MS/MS analysis of human MDH2 314-AcK. The tandem mass spectrum of
the peptides (residues 308-324) VSSFEEK*MISDAIPELK (ion score 79) from purified hMDH2
with one amber codon at position 314. K* denotes AcK incorporation. The partial sequence of
the peptide containing the AcK can be read from the annotated b or y ion series.
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Figure 2.S9. Western blotting of acetylated hMDH2 variants treated with SIRT3. The
acetylation levels of hMDH2 variants after 2-hour incubation were compared with those without
SIRT3 treatment. The reaction was performed in buffer contains 40 mM HEPES (pH 7.0), 6 mM
MgCl2, 1.0 mM NAD+, 1 mM DTT and 10 % glycerol. 10 μg hMDH2 variants, 10 μg SIRT3,
and the reaction buffer were incubated at 37 °C in a total volume of 100 μl.

Figure S10. In vitro acetylation of E. coli MDH by 25 GNAT family members. Western
blotting of purified eMDH from BL21(DE3) cells treated with candidate acetyltransferases and
acetyl CoA for 2 hours. The same amounts of proteins were loaded. Lane 1 is eMDH incubated
with acetyl CoA only; the proteins from Lane 2 to Lane 26 are YiaC, YjhQ, YhbS, YafP, ElaA,
YjdJ, YedL, YpeA, YhhY, YjaB, YiiD, YjgM, WecD, ArgA, AstA, CitC, MnaT, PanM, PhnO,
RimI, RimJ, RimL, SpeG, TmcA, and YfiQ, individually. The bands at other sizes indicated the
acetylation of candidate acetyltransferases.
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Supplementary Data for Chapter 3
Table 3.S1. The list of strains with plasmids used in this study.

*: OTS is the abbreviation for orthogonal translational modification.
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Figure 3.S1. LC-MS/MS analysis of ICDH 55-AcK. The tandem mass spectrum of the peptide
(residues 48- 61) VVDAAVEKACAYKGER from purified ICDH 55-AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series. Matched peaks are in red.
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Figure 3.S2. LC-MS/MS analysis of ICDH 100-AcK. The tandem mass spectrum of the
peptide (residues 97- 112) VAIKACGPLTTPVGGGIR from purified ICDH 100-AcK. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated b or y ion series. Matched peaks are in red.
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Figure 3.S3. LC-MS/MS analysis of ICDH 142-AcK. The tandem mass spectrum of the
peptide (residues 133-153) YYQGTPSPVKACHPELTDMVIFR from purified ICDH 142-AcK.
KAC denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be
read from the annotated a, b or y ion series. Matched peaks are in red.
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Figure 3.S4. LC-MS/MS analysis of ICDH 177-AcK. The tandem mass spectrum of the
peptide (residues 175-180) VIKACFLR from purified ICDH 177-AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series. Matched peaks are in red.
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Figure S5. LC-MS/MS analysis of ICDH 230-AcK. The tandem mass spectrum of the peptide
(residues 223-235) DSVTLVHKACGNIMK from purified ICDH 230-AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 3.S6. LC-MS/MS analysis of ICDH 235-AcK. The tandem mass spectrum of the
peptide (residues 231-242) GNIMKACFTEGAFK from purified ICDH 235-AcK. KAC denotes
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series. Matched peaks are in red.
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Figure 3.S7. LC-MS/MS analysis of ICDH 242- AcK. The tandem mass spectrum of the
peptide (residues 236-250) FTEGAFKACDWGYQLAR from purified ICDH 242-AcK. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated y ion series. Matched peaks are in red.
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Figure 3.S8. LC-MS/MS analysis of ICDH 350-AcK. The tandem mass spectrum of the
peptide (residues 345-365) YAGQDKACVNPGSIILSAEMMLR from purified ICDH 350-AcK.
KAC denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be
read from the annotated a, b or y ion series. Matched peaks are in red.
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Figure 3.S9. MALDI-TOF mass spectra. Purified wild-type ICDH (upper) and ICDH 55-AcK
(lower) as a representative acetylated ICDH variant. The single weak of acetylated ICDH
indicated homogeneous incorporation of acetyllysine.
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Figure 3.S10. LC-MS/MS analysis of ICDH 55AcK/100AcK. The tandem mass spectrum of
the peptide (residues 48-58) VVDAAVEKACAYK (upper) and the peptide (residues 97-112)
VAIKACGPLTTPVGGGIR (lower) from the purified ICDH 55AcK/100AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series.
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Figure 3.S11. LC-MS/MS analysis of ICDH 55AcK/142AcK. The tandem mass spectrum of
the peptide (residues 48-58) VVDAAVEKACAYK (upper) and the peptide (residues 133-153)
YYQGTPSPVKACHPELTDMVIFR (lower) from the purified ICDH 55AcK/142AcK. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated a, b or y ion series.
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Figure 3.S12. LC-MS/MS analysis of ICDH 55AcK/177AcK. The tandem mass spectrum of
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 167180) ADSADAEKVIKACFLR (lower) from the purified ICDH 55AcK/177AcK. KAC denotes
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series.
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Figure 3.S13. LC-MS/MS analysis of ICDH 55AcK/230AcK. The tandem mass spectrum of
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 212230) AAIEYAIANDRDSVTLVHKAC (lower) from the purified ICDH 55AcK/230AcK. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated a, b or y ion series.
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Figure 3.S14. LC-MS/MS analysis of ICDH 55AcK/235AcK. The tandem mass spectrum of
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 231250) GNIMKACFTEGAFKDWGYQLAR (lower) from the purified ICDH 55AcK/235AcK. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated a, b or y ion series.
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Figure 3.S15. LC-MS/MS analysis of ICDH 55AcK/242AcK. The tandem mass spectrum of
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 236250) FTEGAFKACDWGYQLAR (lower) from the purified ICDH 55AcK/242AcK. KAC denotes
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series.
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Figure 3.S16. LC-MS/MS analysis of ICDH 55AcK/350AcK. The tandem mass spectrum of
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 345365) YAGQDKACVNPGSIILSAEMMLR (lower) from the purified ICDH 55AcK/350AcK. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated a, b or y ion series.
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Figure 3.S17. MALDI- TOF mass spectra. Purified wild-type ICDH (upper) and ICDH
55AcK/100AcK (lower) as a representative dual-acetylated ICDH variant. The single weak of
dual-acetylated ICDH indicated simultaneous incorporation of acetyllysine at two lysine sites.

141

Figure 3.S18. Mapping of acetylation sites on the crystal structure of ICDH. The crystal
structure of the ICDH dimer (PDB ID: 4aj3) was demonstrated with the selected acetylation sites
labelled. Two subunits were colored with red and blue separately.
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Figure 3.S19. In vitro deacetylation of RutR by YcgC. SDS-PAGE and western blotting of
RutR treated with the YcgC protein.
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Figure 3.S20. In vitro acetylation assays of ICDH with YfiQ. A) SDS-PAGE and western
blotting of ICDH treated with the YfiQ protein and 200 µM acetyl- CoA. B) SDS-PAGE and
western blotting of RcsB treated with the YfiQ protein. RcsB is a known substrate of YfiQ and
was used to show the purified YfiQ protein was active.
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Figure 3.S21. LC-MS/MS spectrum of the peptide (residues 1-12). MESKACVVVPAQGK
from acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of
the peptide containing the AcK can be read from the annotated a, b or y ion series. Matched
peaks are in red.
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Figure 3.S22. LC-MS/MS spectrum of the peptide (residues 14-47). ITLQNGKAC
LNVPENPIIP-YIEGDGIGVDVTPAMLK from acetyl-phosphate-treated ICDH. KAC denotes
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series. Matched peaks are in red.
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Figure 3.S22. LC-MS/MS spectrum of the peptide (residues 14-47). (Cont)ITLQNGKAC
LNVPENPIIP-YIEGDGIGVDVTPAMLK from acetyl-phosphate-treated ICDH. KAC denotes
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series. Matched peaks are in red.
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Figure 3.S23. LC-MS/MS spectrum. Peptide (residues 21-55) LNVPENPIIPYIEGDGIGVDVTPAMLKACVVDAAVEK from acetyl-phosphate-treated ICDH. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 3.S23. LC-MS/MS spectrum (Cont.). Peptide (residues 21-55)
LNVPENPIIPYIEGDGIGVDV-TPAMLKACVVDAAVEK from acetyl-phosphate-treated
ICDH. KAC denotes AcK incorporation. The partial sequence of the peptide containing the AcK
can be read from the annotated b or y ion series. Matched peaks are in red.
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Figure 3.S24. LC-MS/MS spectrum. Peptide (residues 73-84) KACISWMEIYTGEK from
acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of the
peptide containing the AcK can be read from the annotated a, b or y ion series. Matched peaks
are in red.
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Figure 3.S25. LC-MS/MS spectrum. Peptide (residues 154-174) ENSEDIYAGIEWKACADSADAEK from acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial
sequence of the peptide containing the AcK can be read from the annotated b or y ion series.
Matched peaks are in red.
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Figure 3.S26. LC-MS/MS spectrum. Peptide (residues 167-177) ADSADAEKACVIK from
acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of the
peptide containing the AcK can be read from the annotated b or y ion series. Matched peaks are
in red.
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Figure 3.S27. LC-MS/MS spectrum. Peptide (residues 251-267) EEFGGELIDGGPWLKACVK
from acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of
the peptide containing the AcK can be read from the annotated b or y ion series. Matched peaks
are in red.
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Figure 3.S28. LC-MS/MS spectrum. Peptide (residues 268-278) NPNTGKACEIVIK from
acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of the
peptide containing the AcK can be read from the annotated b or y ion series. Matched peaks are
in red.
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Figure 3.S29. LC-MS/MS spectrum. Peptide (residues 274-292)
EIVIKACDVIADAFLQQILLR from acetyl-phosphate-treated ICDH. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated a, b or y ion series. Matched peaks are in red.
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Figure 3.S30. LC-MS/MS spectrum. Peptide (residues 366- 387)
HMGWTEAADLIVKACGME-GAINAK from acetyl-phosphate-treated ICDH. KAC denotes
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure S31. LC-MS/MS spectrum. Peptide (residues 379-395) GMEGAINAKACTVTYDFER
from acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of
the peptide containing the AcK can be read from the annotated b or y ion series. Matched peaks
are in red.
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Supplementary Data for Chapter 4
Table 4.S1. The list of strains with plasmids used in this study.
Strain

Plasmid or Sources

BW25113

Lab directory

BW25113

Keio collection

BW25113

Keio collection

BW25113

Keio collection

BW25113

Keio collection

BW25113

Keio collection

BW25113

Lab directory

AG1

pCA24N-CobB (AKSA collection)

AG1

pCA24N-YfiQ (AKSA collection)

AG1

pCA24N-RcsB (AKSA collection)

BL21(DE3)

pCDF-CS

BL21(DE3)

pCDF-CS (38TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (168TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (283TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (295TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (310TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (328TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (356TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (405TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (418TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (422TAG) + pTech-AcK-OTS

BL21(DE3)

pCDF-CS (283TAG/295TAG) + pTech-AcK-OTS

*: OTS is the abbreviation for orthogonal translational modification.
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47878

47919

Figure 4.S1. MALDI -TOF mass spectra of CS. Purified wild-type CS (upper, 47878 Da) and
CS 38-AcK (lower, 47919 Da) as a representative of acetylated CS variants. The single peak of
acetylated CS (ΔMW = 41 Da) indicated homogeneous incorporation of acetyllysine.
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Figure 4.S2. LC-MS/MS analysis of CS 38-AcK. The tandem mass spectrum of the peptide
(residues 34-56) TLGSKAC GVFTFDPGFTSTASCESK from purified CS 38-AcK. KAC denotes
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 4.S3. LC-MS/MS analysis of CS 168- AcK. The tandem mass spectrum of the peptide
(residues 165-178) LLSKACMPTMAAMCYK from purified CS 168-AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 4.S4. LC-MS/MS analysis of CS 283-AcK. The tandem mass spectrum of the peptide
(residues 275-290) MLEEISSVKACHIPEFVR from purified CS 283-AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 4.S5. LC-MS/MS analysis of CS 295-AcK. The tandem mass spectrum of the peptide
(residues 292-300) AKDKACNDSFR from purified CS 295-AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 4.S6. LC-MS/MS analysis of CS 310-AcK. The tandem mass spectrum of the peptide
(residues 308-315) VYKACNYDPR from purified CS 310-AcK. KAC denotes AcK incorporation.
The partial sequence of the peptide containing the AcK can be read from the annotated b or y ion
series. Matched peaks are in red.

164

Figure 4.S7. LC-MS/MS analysis of CS 328-AcK. The tandem mass spectrum of the peptide
(residues 321-333) ETCHEVLKACELGTK from purified CS 328-AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 4.S8. LC-MS/MS analysis of CS 356-AcK. The tandem mass spectrum of the peptide
(residues 334-357) DDLLEVAMELENIALNDPYFIEKACK from purified CS 356-AcK. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated b or y ion series. Matched peaks are in red.

166

Figure 4.S9. LC-MS/MS analysis of CS 405-AcK. The tandem mass spectrum of the peptide
(residues 389-408) TVGWIAHWSEMHSDGMKACIAR from purified CS 405-AcK. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated b or y ion series. Matched peaks are in red.
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Figure 4.S10. LC-MS/MS analysis of CS 418-AcK. The tandem mass spectrum of the peptide
(residues 411-422) QLYTGYEKACRDFK from purified CS 418-AcK. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 4.S11. LC-MS/MS analysis of CS 422-AcK. The tandem mass spectrum of the peptide
(residues 420-426) DFKACSDIK from purified CS 422-AcK. KAC denotes AcK incorporation.
The partial sequence of the peptide containing the AcK can be read from the annotated b or y ion
series. Matched peaks are in red.
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Figure 4.S12. LC-MS/MS analysis of CS 7-AcK. The tandem mass spectrum of the peptide
(residues 6-22) AKACLTLNGDTAVELDVLK from the AcP-treated CS. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 4.S13. LC-MS/MS analysis of CS 22-AcK. The tandem mass spectrum of the peptide
(residues 8-33) LTLNGDTAVELDVLKACGTLGQDVIDIR from the AcP-treated CS. KAC
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read
from the annotated b or y ion series. Matched peaks are in red.
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Figure 4.S14. LC- MS/MS analysis of CS 56-AcK. The tandem mass spectrum of the peptide
(residues 39- 56) GVFTFDPGFTSTASCESKAC from the AcP-treated CS. KAC denotes AcK
incorporation. The partial sequence of the peptide containing the AcK can be read from the
annotated b or y ion series. Matched peaks are in red.
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Figure 4.S15. LC-MS/MS analysis of CS 293- AcK. The tandem mass spectrum of the peptide
(residues 292-300) AKACDKNDSFR from the AcP-treated CS. KAC denotes AcK incorporation.
The partial sequence of the peptide containing the AcK can be read from the annotated b or y ion
series. Matched peaks are in red.
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Figure 4.S16. LC-MS/MS analysis of CS 333-AcK. The tandem mass spectrum of the peptide
(residues 329-356) ELGTKACDDLLEVAMELENIALNDPYFIEK from the AcP-treated CS.
KAC denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be
read from the annotated b or y ion series. Matched peaks are in red.
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Figure 4.S17. The CD spectra were recorded on a J-1500 CD Spectrometer (JASCO
Corporation, Tokyo, Japan). Purified enzymes were diluted to a concentration of 0.1 mg/mL in
5 mM Tris/HCl pH 7.8, 0.1 M KCl, and scanned from 190 nm to 250 nm with a 20 nm/min
speed. Scanning was performed three times for each sample and the average was plotted.
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